BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017;35:3924-33. [PMID: 29023213 DOI: 10.1200/JCO.2017.74.3062] [Cited by in Crossref: 473] [Cited by in F6Publishing: 545] [Article Influence: 78.8] [Reference Citation Analysis]
Number Citing Articles
1 Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP. Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncol 2023. [PMID: 36701150 DOI: 10.1001/jamaoncol.2022.6901] [Reference Citation Analysis]
2 Palanivelu L, Liu C, Lin L. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1038226] [Reference Citation Analysis]
3 Wu N, Ge W, Quek RG, Gleeson M, Pouliot JF, Dietz H, Jalbert JJ, Harnett J, Antonia SJ. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer. Future Oncol 2023. [PMID: 36656547 DOI: 10.2217/fon-2022-0540] [Reference Citation Analysis]
4 Banavasi H, Kim S, Alkassis S, Daoud A, Laktineh A, Nagasaka M, Sukari A, Soubani AO. Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes. Hematol Oncol Stem Cell Ther 2023;16:144-50. [PMID: 34688626 DOI: 10.1016/j.hemonc.2021.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen ZH, Zheng WH, Wu CF, Kou J, Yang XL, Lin L, Lv JW, Sun Y, Zhou GQ. Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. BMC Med 2023;21:18. [PMID: 36647058 DOI: 10.1186/s12916-022-02697-3] [Reference Citation Analysis]
6 Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol 2023. [PMID: 36639452 DOI: 10.1038/s41571-022-00718-x] [Reference Citation Analysis]
7 Zhang X, Jiang D, Li S, Zhang X, Zheng W, Cheng B. A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. Front Oncol 2022;12:1023833. [PMID: 36713530 DOI: 10.3389/fonc.2022.1023833] [Reference Citation Analysis]
8 Zhou Q, Liu X, Li J, Tong B, Xu Y, Chen M, Liu X, Gao X, Shi Y, Zhao J, Zhong W, Wang M. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Thorac Cancer 2023. [PMID: 36630992 DOI: 10.1111/1759-7714.14767] [Reference Citation Analysis]
9 Bjørnhart B, Kristiansen C, Asmussen J, Hansen KH, Wedervang K, Jørgensen TL, Herrstedt J, Schytte T. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy. Thromb Res 2023;221:164-72. [PMID: 36396518 DOI: 10.1016/j.thromres.2022.10.020] [Reference Citation Analysis]
10 Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
11 Tamayo-Bermejo R, Del Rio-Valencia JC, Mora-Rodriguez B, Muñoz-Castillo I. Effectiveness and safety of pembrolizumab monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer. J Oncol Pharm Pract 2023;29:138-44. [PMID: 34931913 DOI: 10.1177/10781552211061117] [Reference Citation Analysis]
12 Yan J, Wu X, Zhu Y, Cang S. Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response. J Cancer Res Clin Oncol 2023;149:343-56. [PMID: 36595044 DOI: 10.1007/s00432-022-04566-1] [Reference Citation Analysis]
13 Hong G, Sun P, Chung C, Park D, Lee SI, Kim N, Lee SE, Lee JE, Kang YE, Kang DH. Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2023;149:159-71. [PMID: 36472770 DOI: 10.1007/s00432-022-04500-5] [Reference Citation Analysis]
14 Rakaee M, Adib E, Ricciuti B, Sholl LM, Shi W, Alessi JV, Cortellini A, Fulgenzi CAM, Viola P, Pinato DJ, Hashemi S, Bahce I, Houda I, Ulas EB, Radonic T, Väyrynen JP, Richardsen E, Jamaly S, Andersen S, Donnem T, Awad MM, Kwiatkowski DJ. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC. JAMA Oncol 2023;9:51-60. [PMID: 36394839 DOI: 10.1001/jamaoncol.2022.4933] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lengyel CG. Mechanisms of Resistance to Immunotherapies in Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_335-1] [Reference Citation Analysis]
16 Zhu Y, Yan C, Wang X, Xu Z, Lv J, Xu X, Yu W, Zhou M, Yue L. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy. Cancer Biol Ther 2022;23:104-11. [PMID: 35239432 DOI: 10.1080/15384047.2021.2011643] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
17 Elsaka RO, Helal SM, Abdelhady AM, Kolaib NM, Soliman MA. Immunohistochemical expression of CD8, CTLA4, and PD-L1 in NSCLC of smokers versus non smokers and its effect on prognosis. Alexandria Journal of Medicine 2022;58:92-101. [DOI: 10.1080/20905068.2022.2101083] [Reference Citation Analysis]
18 Yi M, Li T, Niu M, Wu Y, Zhao Z, Wu K. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy. Front Immunol 2022;13:1061394. [PMID: 36601124 DOI: 10.3389/fimmu.2022.1061394] [Reference Citation Analysis]
19 Wang F, Yu C, Chen L, Xu S. Landscape of circular RNAs in different types of lung cancer and an emerging role in therapeutic resistance (Review). Int J Oncol 2023;62:21. [PMID: 36562354 DOI: 10.3892/ijo.2022.5469] [Reference Citation Analysis]
20 Ioannis A. Vathiotis, Leonidas Salichos, Sandra Martinez-Morilla, Niki Gavrielatou, Thazin Nwe Aung, Saba Shafi, Pok Fai Wong, Shlomit Jessel, Harriet M. Kluger, Konstantinos N. Syrigos, Sarah Warren, Mark Gerstein, David L. Rimm. Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. NPJ Precis Oncol 2022;6:92. [PMID: 36522538 DOI: 10.1038/s41698-022-00330-3] [Reference Citation Analysis]
21 Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Cotté FE, Audigier-Valette C, Griesinger F. Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers (Basel) 2022;14. [PMID: 36551632 DOI: 10.3390/cancers14246148] [Reference Citation Analysis]
22 Yudin DI, Laktionov KK, Moiseenko FV, Ponomarenko DM, Chekh EA, Chubenko VA, Levchenko NV, Kozlov VV, Stepanova EО, Sarantseva KA, Denisova ES, Ardzinba MS, Yukalchuk DY. First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-22-12-20] [Reference Citation Analysis]
23 Khouzam MS, Wood DE, Vigneswaran W, Goyal A, Czerlanis C, Blackmon SH, Donington J, Albain KS, Freeman RK, Abdelsattar ZM. Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer. Ann Thorac Surg 2022:S0003-4975(22)01500-4. [PMID: 36470567 DOI: 10.1016/j.athoracsur.2022.11.021] [Reference Citation Analysis]
24 Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, Sadat Hosseini G, Gholami N, Janati S. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology 2022;113:109365. [DOI: 10.1016/j.intimp.2022.109365] [Reference Citation Analysis]
25 Fomchenko EI, Bayley JC, Alvarez-Breckenridge C, Rhines LD, Tatsui CE. Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. Neurospine 2022;19:978-93. [PMID: 36597635 DOI: 10.14245/ns.2244290.145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Deng H, Liang H, Chen J, Wang W, Li J, Xiong S, Cheng B, Li C, Chen Z, Wang H, Zheng J, Guo Z, He J, Liang W. Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers. Transl Lung Cancer Res 2022;11:2364-81. [PMID: 36636407 DOI: 10.21037/tlcr-22-439] [Reference Citation Analysis]
27 Frank AJ, Dagogo-Jack I, Dobre IA, Tait S, Schumacher L, Fintelmann FJ, Fingerman LM, Keane FK, Montesi SB. Management of Lung Cancer in the Patient with Interstitial Lung Disease. Oncologist 2023;28:12-22. [PMID: 36426803 DOI: 10.1093/oncolo/oyac226] [Reference Citation Analysis]
28 Wlosik J, Fattori S, Rochigneux P, Goncalves A, Olive D, Chretien AS. Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. Semin Immunopathol 2022. [DOI: 10.1007/s00281-022-00973-1] [Reference Citation Analysis]
29 Kuo W, Weng C, Lien Y. Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1023894] [Reference Citation Analysis]
30 Liu R, He X, Li Z. Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1029598] [Reference Citation Analysis]
31 Luo K, Liu S, Shen X, Xu J, Shi C, Chao Y, Wen Z, Zhang K, Wang R, Liu B, Jiang Y. Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1003656] [Reference Citation Analysis]
32 Bortolotto C, Stella GM, Messana G, Lo Tito A, Podrecca C, Nicora G, Bellazzi R, Gerbasi A, Agustoni F, Grimm R, Zacà D, Filippi AR, Bottinelli OM, Preda L. Correlation between PD-L1 Expression of Non-Small Cell Lung Cancer and Data from IVIM-DWI Acquired during Magnetic Resonance of the Thorax: Preliminary Results. Cancers (Basel) 2022;14. [PMID: 36428726 DOI: 10.3390/cancers14225634] [Reference Citation Analysis]
33 Liu SM, Yan HH, Wei XW, Lu C, Dong XR, Du Y, Cui JW, Chen Y, Ma R, Wang BH, Zhou Z, Cang SD, Yang JJ, Tu HY, Zhang XC, Zhong WZ, Zhou Q, Wu YL. Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705). Clin Lung Cancer 2022;23:e395-9. [PMID: 35659479 DOI: 10.1016/j.cllc.2022.05.009] [Reference Citation Analysis]
34 Fang X, Yu S, Jiang Y, Xiang Y, Lu K. Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1027664] [Reference Citation Analysis]
35 Zeng C, Yu H, Liu X, Liu Q, Jin J. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma. BioMed Research International 2022;2022:1-31. [DOI: 10.1155/2022/9710540] [Reference Citation Analysis]
36 Zhang C, Song X, Wang C. COL22A1 and DNAH8 mutations are associated with tumor mutation burden and prognosis of lung adenocarcinoma patients.. [DOI: 10.21203/rs.3.rs-2162636/v1] [Reference Citation Analysis]
37 Yu C, Jiang L, Yang D, Dong X, Yu R, Yu H. Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment. Onco Targets Ther 2022;15:1221-8. [PMID: 36262804 DOI: 10.2147/OTT.S380615] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Sun D, Qian H, Wang J, Xie T, Teng F, Li J, Xing P. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production. Cell Commun Signal 2022;20:156. [PMID: 36229854 DOI: 10.1186/s12964-022-00958-5] [Reference Citation Analysis]
39 Xie D, Xu F, Zhu W, Pu C, Huang S, Lou K, Wu Y, Huang D, He C, Hu H. Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. Front Oncol 2022;12:990608. [DOI: 10.3389/fonc.2022.990608] [Reference Citation Analysis]
40 Monastirioti A, Papadaki C, Kalapanida D, Rounis K, Michaelidou K, Papadaki MA, Mavroudis D, Agelaki S. Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab. Cancers 2022;14:4739. [DOI: 10.3390/cancers14194739] [Reference Citation Analysis]
41 Li Z, Zhou Q, Wang Q, Wang H, Yue W. EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers. BMC Pulm Med 2022;22:356. [PMID: 36123678 DOI: 10.1186/s12890-022-02161-1] [Reference Citation Analysis]
42 Akazawa Y, Yoshikawa A, Kanazu M, Yano Y, Yamaguchi T, Mori M. Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. Thorac Cancer 2022;13:2450-8. [PMID: 35820673 DOI: 10.1111/1759-7714.14576] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Chandrasekaran J, Elumalai S, Murugesan V, Kunjiappan S, Pavadai P, Theivendren P. Computational design of PD-L1 small molecule inhibitors for cancer therapy. Mol Divers 2022. [PMID: 36006501 DOI: 10.1007/s11030-022-10516-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Chen Y, Jian T, Shen Y. Immune Checkpoint Inhibitors in Lung Cancer. HSET 2022;8:111-120. [DOI: 10.54097/hset.v8i.1117] [Reference Citation Analysis]
45 Nakagawa N, Kawakami M. Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Front Oncol 2022;12:952393. [DOI: 10.3389/fonc.2022.952393] [Reference Citation Analysis]
46 Yang W, Xuan B, Chen M, Li X, He J, Si H, Zhang Y. Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. Front Oncol 2022;12:883514. [DOI: 10.3389/fonc.2022.883514] [Reference Citation Analysis]
47 Evans R, Lee K, Wallace PK, Reid M, Muhitch J, Dozier A, Mesa C, Luaces PL, Santos-morales O, Groman A, Cedeno C, Cinquino A, Fisher DT, Puzanov I, Opyrchal M, Fountzilas C, Dai T, Ernstoff M, Attwood K, Hutson A, Johnson C, Mazorra Z, Saavedra D, Leon K, Lage A, Crombet T, Dy GK. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC. Front Oncol 2022;12:958043. [DOI: 10.3389/fonc.2022.958043] [Reference Citation Analysis]
48 Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X, Hou R, Ma W, Liu D, Zheng J, Shi M. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. Front Immunol 2022;13:920021. [DOI: 10.3389/fimmu.2022.920021] [Reference Citation Analysis]
49 Lin EP, Hsu CY, Berry L, Bunn P, Shyr Y. Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses. JAMA Netw Open 2022;5:e2227211. [PMID: 35976648 DOI: 10.1001/jamanetworkopen.2022.27211] [Reference Citation Analysis]
50 Bredin P, Naidoo J. The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. Cancer Metastasis Rev 2022. [PMID: 35876944 DOI: 10.1007/s10555-022-10039-1] [Reference Citation Analysis]
51 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
52 Wu K, Xia B, Zhang J, Li X, Yang S, Zhang M, Zhu L, Wang B, Xu X, Ma S, Chen X. Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers 2022;14:3568. [DOI: 10.3390/cancers14153568] [Reference Citation Analysis]
53 Oosting LT, Franke K, Martin MV, Kloosterman WP, Jamieson JA, Glenn LA, de Jager MW, van Zanten J, Allersma DP, Gareb B. Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer. Pharmaceutics 2022;14:1515. [DOI: 10.3390/pharmaceutics14071515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Liu J, Ma J, Xing N, Ji Z, Li J, Zhang S, Guo Z. Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04201-z] [Reference Citation Analysis]
55 Gouez M, Delrieu L, Bouleuc C, Girard N, Raynard B, Marchal T. Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study. Cancers (Basel) 2022;14:3439. [PMID: 35884500 DOI: 10.3390/cancers14143439] [Reference Citation Analysis]
56 Kang DH, Choi SW, Sun P, Chung C, Park D, Lee SI, Koh JS, Kim Y, Lee JE. The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer. Thorac Cancer 2022. [PMID: 35818294 DOI: 10.1111/1759-7714.14568] [Reference Citation Analysis]
57 Choi S, Cho SI, Ma M, Park S, Pereira S, Aum BJ, Shin S, Paeng K, Yoo D, Jung W, Ock C, Lee S, Choi Y, Chung J, Mok TS, Kim H, Kim S. Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response. European Journal of Cancer 2022;170:17-26. [DOI: 10.1016/j.ejca.2022.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
58 Freemantle N, Xu Y, Wilson FR, Guyot P, Chen CI, Keeping S, Konidaris G, Chan K, Kuznik A, Atsou K, Glowienka E, Pouliot JF, Gullo G, Rietschel P. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50. Ther Adv Med Oncol 2022;14:17588359221105024. [PMID: 35747163 DOI: 10.1177/17588359221105024] [Reference Citation Analysis]
59 Su X, Zhou X, Xiao C, Peng W, Wang Q, Zheng Y. Complete Response to Immunotherapy Combined With Chemotherapy in a Patient With Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma With High Tumor Mutational Burden: A Case Report. Front Oncol 2022;12:750970. [DOI: 10.3389/fonc.2022.750970] [Reference Citation Analysis]
60 Li F, Liao B, Wang T, Qi T, Wang Y. Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. Front Pharmacol 2022;13:918709. [DOI: 10.3389/fphar.2022.918709] [Reference Citation Analysis]
61 Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov 2022. [PMID: 35701637 DOI: 10.1038/s41573-022-00493-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
62 Batra U, Chufal KS, Nathany S, Ahmad I, Chowdhary RL, Sharma M, Jain P, Gairola M. Immunotherapy in advanced non-small-cell lung cancer (NSCLC) after progression on chemotherapy: real-world results from a prospective institutional cohort. Immunotherapy 2022. [PMID: 35698820 DOI: 10.2217/imt-2021-0170] [Reference Citation Analysis]
63 Kanabar SS, Tiwari A, Soran V, Balendran P, Price M, Turner AM. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax 2022:thoraxjnl-2020-215614. [PMID: 35688624 DOI: 10.1136/thoraxjnl-2020-215614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Liao D, Yu L, Shangguan D, Zhang Y, Xiao B, Liu N, Yang N. Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer. Front Pharmacol 2022;13:905947. [DOI: 10.3389/fphar.2022.905947] [Reference Citation Analysis]
65 Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer 2022;10:e003956. [PMID: 35640927 DOI: 10.1136/jitc-2021-003956] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Shi Y, Ji M, Jiang Y, Yin R, Wang Z, Li H, Wang S, He K, Ma Y, Wang Z, Lu J, Shi M, Shen B, Zhou G, Leong TL, Wang X, Chen C, Feng J. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world. Transl Lung Cancer Res 2022;11:1051-68. [PMID: 35832459 DOI: 10.21037/tlcr-22-350] [Reference Citation Analysis]
67 Galetta D, De Marinis F, Spaggiari L. Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer. Cancers 2022;14:2661. [DOI: 10.3390/cancers14112661] [Reference Citation Analysis]
68 Spieler B, Giret TM, Welford S, Totiger TM, Mihaylov IB. Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study. Biomedicines 2022;10:1173. [DOI: 10.3390/biomedicines10051173] [Reference Citation Analysis]
69 To S, Kao L, Shih J, Li I, Huang T, Tsai C, Chian C, Ho C, Chang P. Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. IJERPH 2022;19:5999. [DOI: 10.3390/ijerph19105999] [Reference Citation Analysis]
70 Yang C, Wei Y, Li W, Wei J, Chen G, Xu M, Liu G, Wang F. Prognostic Risk Signature and Comprehensive Analyses of Endoplasmic Reticulum Stress-Related Genes in Lung Adenocarcinoma. Journal of Immunology Research 2022;2022:1-39. [DOI: 10.1155/2022/6567916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Franchi M, Pellegrini G, Corrao G. Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2022;15:489. [PMID: 35455486 DOI: 10.3390/ph15040489] [Reference Citation Analysis]
72 Li Y, Li C, Jiang Y, Han X, Liu S, Xu X, Tang W, Ou Q, Bao H, Wu X, Shao Y, Xing M, Zhang Y, Wang Y, Lee G. Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/1763778] [Reference Citation Analysis]
73 Liang H, Xu Y, Chen M, Zhao J, Zhong W, Liu X, Gao X, Li S, Li J, Guo C, Jia H, Wang M. Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. Front Immunol 2021;12:749461. [PMID: 35356154 DOI: 10.3389/fimmu.2021.749461] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
74 Lopci E, Hicks RJ, Dimitrakopoulou-strauss A, Dercle L, Iravani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans AWJM, Weber W, Wahl RL, Scott AM, Pandit-taskar N, Aide N. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05780-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
75 Zhang K, Kong X, Li Y, Wang Z, Zhang L, Xuan L. PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. Front Pharmacol 2022;13:854967. [DOI: 10.3389/fphar.2022.854967] [Reference Citation Analysis]
76 Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol 2022. [PMID: 35298698 DOI: 10.1007/s00280-022-04414-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Chen Y, Chen Z, Chen R, Fang C, Zhang C, Ji M, Yang X. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC. Future Oncol 2022. [PMID: 35232247 DOI: 10.2217/fon-2021-0862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Vanderpuye-orgle J, Erim D, Qian Y, Boyne DJ, Cheung WY, Bebb G, Shah A, Pericleous L, Maruszczak M, Brenner DR. Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada. Oncol Ther. [DOI: 10.1007/s40487-022-00187-3] [Reference Citation Analysis]
79 Juarez-garcia A, Sharma R, Hunger M, Kayaniyil S, Penrod JR, Chouaïd C. Real-World Effectiveness of Immunotherapies in Pre-Treated, Advanced Non-Small Cell Lung Cancer Patients: A Systematic Literature Review. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.03.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
80 Capaccione KM, Huang S, D'souza B, Leb J, Luk L, Goldstein J, May B, Deng A, Salvatore MM. Radiographic features of pneumonitis in patients treated with immunotherapy compared to traditional chemotherapy for non-small cell lung cancer. Clinical Imaging 2022. [DOI: 10.1016/j.clinimag.2022.03.006] [Reference Citation Analysis]
81 Aru B, Soltani M, Pehlivanoglu C, Gürlü E, Ganjalikhani-Hakemi M, Yanikkaya Demirel G. Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead. Front Oncol 2022;12:789728. [PMID: 35155232 DOI: 10.3389/fonc.2022.789728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Fu J, Li Y, Li C, Tong Y, Li M, Cang S. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation. Transl Cancer Res 2021;10:3963-78. [PMID: 35116695 DOI: 10.21037/tcr-21-565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Wang Y, Zhou P, Cui C, He X, Bian Y, Wang X. The expression of Nanog protein and fibroblast growth factor-inducible molecule 14 in patients with non-small cell lung cancer and their relationship with pathological characteristics and prognosis. Transl Cancer Res 2021;10:2470-7. [PMID: 35116561 DOI: 10.21037/tcr-21-724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Chouaïd C, Grumberg V, Batisse A, Corre R, Giaj Levra M, Gaudin AF, Prodel M, Lortet-Tieulent J, Assié JB, Cotté FE. Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab. JCO Clin Cancer Inform 2022;6:e2100108. [PMID: 35113656 DOI: 10.1200/CCI.21.00108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Leung JH, Chang CW, Chan AL, Lang HC. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncol 2022. [PMID: 35105168 DOI: 10.2217/fon-2021-0785] [Reference Citation Analysis]
86 Levy B, Barlesi F, Paz-ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim S, Madelaine J, Molinier O, Özgüroğlu M, Rodríguez Abreu D, Adeniji A, Lorence RM, Voccia I, Chisamore MJ, Riess JW. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.023] [Reference Citation Analysis]
87 Kuznik A, Smare C, Chen C, Venkatachalam M, Keeping S, Atsou K, Xu Y, Wilson F, Guyot P, Chan K, Glowienka E, Konidaris G. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%. Value in Health 2022;25:203-14. [DOI: 10.1016/j.jval.2021.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Hou K, Ning Z, Chen H, Wu Y. Nanomaterial Technology and Triple Negative Breast Cancer. Front Oncol 2021;11:828810. [PMID: 35096628 DOI: 10.3389/fonc.2021.828810] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
89 Chen L, Jiang X, Zhang Q, Li Q, Zhang X, Zhang M, Yu Q, Gao D. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.108962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
90 Wu M, Zhang Y, Zhang J, Zhang Y, Wang Y, Chen F, Luo Y, He S, Liu Y, Yang Q, Li Y, Wei H, Zhang H, Lu N, Wang S, Guo Y, Ye Z, Liu Y. A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study. Front Oncol 2021;11:688679. [PMID: 35083133 DOI: 10.3389/fonc.2021.688679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
91 Tjokrowidjaja A, Lord SJ, John T, Lewis CR, Kok PS, Marschner IC, Lee CK. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. Cancer 2022. [PMID: 35090047 DOI: 10.1002/cncr.34113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S, Zhou H. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells 2022;11:320. [DOI: 10.3390/cells11030320] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
93 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. [PMID: 35020204 DOI: 10.3322/caac.21708] [Cited by in Crossref: 1857] [Cited by in F6Publishing: 1933] [Article Influence: 1857.0] [Reference Citation Analysis]
94 Lee YJ, Park YS, Lee HW, Park TY, Lee JK, Heo EY. Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep 2022;12:626. [PMID: 35022510 DOI: 10.1038/s41598-021-04630-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
95 Brueckl NF, Wirtz RM, Reich FPM, Veltrup E, Zeitler G, Meyer C, Wuerflein D, Ficker JH, Eidt S, Brueckl WM. Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2021;10:4106-19. [PMID: 35004242 DOI: 10.21037/tlcr-21-587] [Reference Citation Analysis]
96 Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, Zamani M. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 2022;22:2. [PMID: 34980128 DOI: 10.1186/s12935-021-02407-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
97 Kaulen LD, Lu B, Goldberg S, Baehring JM. Neurological complications of lung cancer. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00027-x] [Reference Citation Analysis]
98 Klastersky JA. The conquest of lung cancer in Central Europe. Curr Opin Oncol 2022;34:32-5. [PMID: 34652285 DOI: 10.1097/CCO.0000000000000803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Wu J, Hou L, E H, Zhao Y, Yu X, Xu L, Ning Y, Deng J, Sun K, Zhang J, Wu C, Zhu Y, Zhao D, She Y, Su C, Chen C. Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
100 Xu B, Cheng H, Li K, Lv Y, Zeng X, Liu T, Yu W, Guo W. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study. J Cancer Res Clin Oncol 2022. [PMID: 34973080 DOI: 10.1007/s00432-021-03873-3] [Reference Citation Analysis]
101 范 晨. Application and Research Progress of Immunosuppressive Agent-Based Systemic System Therapy in Advanced Hepatocellular Carcinoma. ACM 2022;12:3079-3086. [DOI: 10.12677/acm.2022.1244444] [Reference Citation Analysis]
102 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clinicians 2022;72:7-33. [DOI: 10.3322/caac.21708] [Cited by in Crossref: 1983] [Cited by in F6Publishing: 1] [Article Influence: 1983.0] [Reference Citation Analysis]
103 Edwards CJ, Sette A, Cox C, Di Fiore B, Wyre C, Sydoruk D, Yadin D, Hayes P, Stelter S, Bartlett PD, Zuazo M, Garcia-Granda MJ, Benedetti G, Fiaska S, Birkett NR, Teng Y, Enever C, Arasanz H, Bocanegra A, Chocarro L, Fernandez G, Vera R, Archer B, Osuch I, Lewandowska M, Surani YM, Kochan G, Escors D, Legg J, Pierce AJ. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. Br J Cancer 2021. [PMID: 34969998 DOI: 10.1038/s41416-021-01684-4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
104 Park JG, Choi BK, Lee Y, Jang EJ, Woo SM, Lee JH, Kim KH, Hwang H, Choi W, Lee SH, Yoo BC. Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. EPMA J 2021;12:629-45. [PMID: 34956427 DOI: 10.1007/s13167-021-00266-x] [Reference Citation Analysis]
105 Shi Y, Fang J, Zhou C, Liu A, Wang Y, Meng Q, Ding C, Ai B, Gu Y, Yao Y, Sun H, Guo H, Zhang C, Song X, Li J, Xu B, Han Z, Song M, Tang T, Chen P, Lu H, Shui Y, Lou G, Zhang D, Liu J, Liu X, Liu X, Gao X, Zhou Q, Chen M, Zhao J, Zhong W, Xu Y, Wang M. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. Thorac Cancer 2021. [PMID: 34935288 DOI: 10.1111/1759-7714.14274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
106 Song X, Chen Q, Wang J, Mao Q, Xia W, Xu L, Jiang F, Dong G. Clinical and prognostic implications of an immune-related risk model based on TP53 status in lung adenocarcinoma. J Cell Mol Med 2021. [PMID: 34877770 DOI: 10.1111/jcmm.17097] [Reference Citation Analysis]
107 Capaccione KM, Huang S, Toor Z, May B, Deng A, Salvatore MM. Immunotherapy related pericardial effusion on chest CT. Clin Imaging 2021;82:204-9. [PMID: 34890964 DOI: 10.1016/j.clinimag.2021.11.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Filleron T, Bachelier M, Mazieres J, Pérol M, Meyer N, Martin E, Mathevet F, Dauxois JY, Porcher R, Delord JP. Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review. JAMA Netw Open 2021;4:e2139573. [PMID: 34932105 DOI: 10.1001/jamanetworkopen.2021.39573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Chang J, Wu Y, Lu S, Wang J, Mok T, Zhang L, Feng J, Wu L, Tu H, Zhang Y, Luft A, Zhou J, Ma Z, Lu Y, Hu C, Shi Y, Poddubskaya E, Soo RA, Hong Chia Y, Penrod JR, Taylor F, Lawrance R, Blum SI, Sun X, Juarez-garcia A, Moreno-koehler A, Li A, Li A, Cheng Y. Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. Lung Cancer 2021. [DOI: 10.1016/j.lungcan.2021.12.009] [Reference Citation Analysis]
111 Flores R, Patel P, Alpert N, Pyenson B, Taioli E. Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer. JAMA Netw Open 2021;4:e2137508. [PMID: 34919136 DOI: 10.1001/jamanetworkopen.2021.37508] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
112 Zhang J, Wu D, Zhang Z, Long J, Tian G, Wang Y, Ma X, Chen X, Han J, Hu W, Dai L, Nie J, Fang J. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. Technol Cancer Res Treat 2021;20:15330338211039676. [PMID: 34821175 DOI: 10.1177/15330338211039676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Huang C, Yang X. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:777-83. [PMID: 34802209 DOI: 10.3779/j.issn.1009-3419.2021.102.40] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
114 Chen YY, Chang SC, Chang CY, Chang CF, Lai YC, Wei YF, Chen CY. Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients. BMC Cancer 2021;21:1225. [PMID: 34781919 DOI: 10.1186/s12885-021-08920-3] [Reference Citation Analysis]
115 Ba H, Liu L, Peng Q, Chen J, Zhu YD. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer 2021;21:1220. [PMID: 34774004 DOI: 10.1186/s12885-021-08924-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Chen SW, Zhu SQ, Pei X, Qiu BQ, Xiong D, Long X, Lin K, Lu F, Xu JJ, Wu YB. Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC. Mol Cancer 2021;20:144. [PMID: 34753486 DOI: 10.1186/s12943-021-01448-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
117 Jing Z, Zhou R, Zhang N. Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer. Ther Adv Chronic Dis 2021;12:20406223211047306. [PMID: 34729152 DOI: 10.1177/20406223211047306] [Reference Citation Analysis]
118 Denault MH, Melosky B. Immunotherapy in the First-Line Setting in Wild-Type NSCLC. Curr Oncol 2021;28:4457-70. [PMID: 34898579 DOI: 10.3390/curroncol28060378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
119 Rischke N, Schwarz S, Haug U. Anwendung von Immuncheckpointinhibitoren in der Therapie von Lungenkrebs. Onkologe 2021;27:1049-1057. [DOI: 10.1007/s00761-021-01041-3] [Reference Citation Analysis]
120 Zhu GL, Yang KB, Tang SQ, Peng L. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. Cancer Med 2021;10:8272-87. [PMID: 34668660 DOI: 10.1002/cam4.4347] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Burke M, Rashdan S. Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. Front Oncol 2021;11:720759. [PMID: 34660286 DOI: 10.3389/fonc.2021.720759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Lee KE, Bender DA, Koutcher LD, Hyde B, Hur C, Faye AS, Cheng SK. Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer. Cancer 2021. [PMID: 34634130 DOI: 10.1002/cncr.33975] [Reference Citation Analysis]
123 Hu X, Xu H, Xue Q, Wen R, Jiao W, Tian K. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Mol Med 2021;27:126. [PMID: 34620079 DOI: 10.1186/s10020-021-00387-z] [Reference Citation Analysis]
124 Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in translational medicine and clinical practice. Mod Pathol 2021. [PMID: 34611303 DOI: 10.1038/s41379-021-00919-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 17.0] [Reference Citation Analysis]
125 El Husseini K, Piton N, De Marchi M, Grégoire A, Vion R, Blavier P, Thiberville L, Baste JM, Guisier F. Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case-Cohort Study. Cancers (Basel) 2021;13:4915. [PMID: 34638399 DOI: 10.3390/cancers13194915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Kinoshita T, Terai H, Yaguchi T. Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life (Basel) 2021;11:1029. [PMID: 34685400 DOI: 10.3390/life11101029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
127 Hussain K, Cragg MS, Beers SA. Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies. Cancers (Basel) 2021;13:4904. [PMID: 34638388 DOI: 10.3390/cancers13194904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
128 Ni J, Zhou Y, Wu L, Ai X, Dong X, Chu Q, Han C, Wang X, Zhu Z. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiat Oncol 2021;16:177. [PMID: 34526044 DOI: 10.1186/s13014-021-01905-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
129 Ma L, Jin G, Yao K, Yang Y, Chang R, Wang W, Liu J, Zhu Z. Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis. Front Pharmacol 2021;12:699892. [PMID: 34456725 DOI: 10.3389/fphar.2021.699892] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 van der Leest P, Hiddinga B, Miedema A, Aguirre Azpurua ML, Rifaela N, Ter Elst A, Timens W, Groen HJM, van Kempen LC, Hiltermann TJN, Schuuring E. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. Mol Oncol 2021;15:2910-22. [PMID: 34449963 DOI: 10.1002/1878-0261.13090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
131 Kalinka E, Chmielewska I, Wojas-Krawczyk K. Viral Infection and Lung Cancer Immunotherapy. Front Oncol 2021;11:577514. [PMID: 34434887 DOI: 10.3389/fonc.2021.577514] [Reference Citation Analysis]
132 Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Transl Lung Cancer Res 2021;10:3093-105. [PMID: 34430350 DOI: 10.21037/tlcr-21-197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
133 Zhang X, Tian D, Chen Y, Chen C, He LN, Zhou Y, Li H, Lin Z, Chen T, Wang Y, Russo A, Nadal E, Passiglia F, Soo RA, Watanabe S, Moran T, Oh IJ, Fu S, Hong S, Zhang L. Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. Transl Lung Cancer Res 2021;10:3191-202. [PMID: 34430357 DOI: 10.21037/tlcr-21-455] [Reference Citation Analysis]
134 Correale P, Saladino RE, Giannarelli D, Giannicola R, Agostino R, Staropoli N, Strangio A, Del Giudice T, Nardone V, Altomonte M, Pastina P, Tini P, Falzea AC, Imbesi N, Arcati V, Romeo G, Caracciolo D, Luce A, Caraglia M, Giordano A, Pirtoli L, Necas A, Amler E, Barbieri V, Tassone P, Tagliaferri P. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. J Immunother Cancer 2020;8:e000733. [PMID: 32554614 DOI: 10.1136/jitc-2020-000733] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
135 Yudin DI, Laktionov KK, Sarantseva KA, Breder VV, Ardzinba MS, Reutova EV, Borisova OI. Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-9-18-24] [Reference Citation Analysis]
136 Padmanabhan J, Saha B, Powell C, Mo Q, Perez BA, Chellappan S. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. Cancers (Basel) 2021;13:3906. [PMID: 34359807 DOI: 10.3390/cancers13153906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Gan J, Huang Y, Fang W, Zhang L. Research progress in immune checkpoint inhibitors for lung cancer in China. Ther Adv Med Oncol 2021;13:17588359211029826. [PMID: 34349843 DOI: 10.1177/17588359211029826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
138 Okishio K, Morita R, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, Kanai O, Kumagai T, Kibata K, Tsukamoto H, Oizumi S, Fujimoto D, Tanaka H, Mizuno K, Masuda T, Kozuki T, Haku T, Suzuki H, Okamoto I, Hoshiyama H, Yada N, Ohe Y. Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR). ESMO Open 2020;5:e000656. [PMID: 32690620 DOI: 10.1136/esmoopen-2019-000656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
139 Zou W, Lu J, Hao Y. Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. J Inflamm Res 2021;14:3077-88. [PMID: 34267536 DOI: 10.2147/JIR.S311616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Rzhevskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A, Thiery JP, Maslennikova A, Zvyagin AV, Ebrahimi Warkiani M. Emerging role of circulating tumor cells in immunotherapy. Theranostics 2021;11:8057-75. [PMID: 34335980 DOI: 10.7150/thno.59677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
141 Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One 2021;16:e0252041. [PMID: 34197475 DOI: 10.1371/journal.pone.0252041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Crombet Ramos T, Santos Morales O, Dy GK, León Monzón K, Lage Dávila A. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Front Oncol 2021;11:639745. [PMID: 34211836 DOI: 10.3389/fonc.2021.639745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
143 Chi A, He X, Hou L, Nguyen NP, Zhu G, Cameron RB, Lee JM. Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. Cancers (Basel) 2021;13:2924. [PMID: 34208113 DOI: 10.3390/cancers13122924] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
144 Deng H, Liang H, Wang W, Li J, Xiong S, Cheng B, Li C, Ai Q, Chen Z, Wang H, Liang W, He J. Immunochemotherapy as induction treatment in Stage III (N2, N3) Non-small cell lung cancer.. [DOI: 10.1101/2021.06.03.21257757] [Reference Citation Analysis]
145 Dumoulin DW, Dingemans AC, Aerts JGJV, Remon J, De Ruysscher DKM, Hendriks LEL. Immunotherapy in small cell lung cancer: one step at a time: a narrative review. Transl Lung Cancer Res 2021;10:2970-87. [PMID: 34295691 DOI: 10.21037/tlcr-20-630] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
146 Schank TE, Forschner A, Sachse MM, Dimitrakopoulou-Strauss A, Sachpekidis C, Stenzinger A, Volckmar AL, Enk A, Hassel JC. Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers (Basel) 2021;13:2616. [PMID: 34073477 DOI: 10.3390/cancers13112616] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
147 Chen B, Yang M, Li K, Li J, Xu L, Xu F, Xu Y, Ren D, Zhang J, Liu L. Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer. Oncol Lett 2021;22:540. [PMID: 34084219 DOI: 10.3892/ol.2021.12801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
148 Ikeda M, Koh Y, Teraoka S, Sato K, Oyanagi J, Hayata A, Tokudome N, Akamatsu H, Ozawa Y, Endo K, Higuchi M, Nakanishi M, Ueda H, Yamamoto N. Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers (Basel) 2021;13:2290. [PMID: 34064720 DOI: 10.3390/cancers13102290] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
149 Suwinski R. Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer. J Thorac Dis 2021;13:3315-22. [PMID: 34164224 DOI: 10.21037/jtd-2019-rbmlc-08] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Korphaisarn K, Danchaivijitr P, Reungwetwattana T, Chewaskulyong B, Thongthieang L, Chindaprasirt J, Maneenil K, Sathitruangsak C, Vinayanuwattikun C. Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. Front Oncol 2021;11:572740. [PMID: 33996532 DOI: 10.3389/fonc.2021.572740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Zhou C, Wang J, Wang B, Cheng Y, Wang Z, Han B, Lu Y, Wu G, Zhang L, Song Y, Zhu B, Hu Y, Wang Z, Song Q, Ren S, He Y, Hu X, Zhang J, Yao Y, Zhao H, Wang Z, Chu Q, Duan J, Liu J, Qin S. [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)]. Zhongguo Fei Ai Za Zhi 2021;24:217-35. [PMID: 33896153 DOI: 10.3779/j.issn.1009-3419.2021.101.13] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
152 Ye H, Pang H, Shi X, Ren P, Huang S, Yu H, Wu J, Lin S. Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial. Front Oncol 2021;11:657024. [PMID: 33968760 DOI: 10.3389/fonc.2021.657024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
153 Yu XH, Huang J, Ge NJ, Yang YF, Zhao JY. Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by pembrolizumab: A case report. World J Clin Cases 2021; 9(10): 2281-2288 [PMID: 33869604 DOI: 10.12998/wjcc.v9.i10.2281] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
154 Pous A, Izquierdo C, Cucurull M, Sánchez S, Lezcano C, Domenech M, Llobera L, Plaja A, Moran T. Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen. Transl Lung Cancer Res 2021;10:1917-23. [PMID: 34012801 DOI: 10.21037/tlcr-20-1315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
155 Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Matsumoto H, Hirano K, Kominami R, Tomii K, Suzuki H, Hirashima T, Tanaka S, Uchida J, Morita M, Kanazu M, Mori M, Nagata K, Fukuda I, Tamiya M. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. BMC Cancer 2021;21:346. [PMID: 33794809 DOI: 10.1186/s12885-021-08048-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
156 Yang J, Xia H, Sun F, Zhang P, Jiang G. Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report. Ann Transl Med 2021;9:724. [PMID: 33987422 DOI: 10.21037/atm-21-1565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Li B, Jiang C, Pang L, Zou B, Ding M, Sun X, Yu J, Wang L. Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review. Front Immunol 2021;12:627197. [PMID: 33859637 DOI: 10.3389/fimmu.2021.627197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
158 von Itzstein MS, Khan S, Gerber DE. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. Clin Chem 2020;66:779-93. [PMID: 32363387 DOI: 10.1093/clinchem/hvaa081] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 19.5] [Reference Citation Analysis]
159 Athie A, Marchese FP, González J, Lozano T, Raimondi I, Juvvuna PK, Abad A, Marin-Bejar O, Serizay J, Martínez D, Ajona D, Pajares MJ, Sandoval J, Montuenga LM, Kanduri C, Lasarte JJ, Huarte M. Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion. J Cell Biol 2020;219:e201908078. [PMID: 32858747 DOI: 10.1083/jcb.201908078] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
160 Vermunt MAC, van der Heijden LT, Hendrikx JJMA, Schinkel AH, de Weger VA, van der Putten E, van Triest B, Bergman AM, Beijnen JH. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours. Cancer Chemother Pharmacol 2021;87:855-69. [PMID: 33744986 DOI: 10.1007/s00280-021-04259-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
161 Liu Y, Wu M, Zhang Y, Luo Y, He S, Wang Y, Chen F, Liu Y, Yang Q, Li Y, Wei H, Zhang H, Jin C, Lu N, Li W, Wang S, Guo Y, Ye Z. Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2021;11:657615. [PMID: 33816314 DOI: 10.3389/fonc.2021.657615] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
162 Mencoboni M, Ceppi M, Bruzzone M, Taveggia P, Cavo A, Scordamaglia F, Gualco M, Filiberti RA. Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis. Cancers (Basel) 2021;13:1388. [PMID: 33808533 DOI: 10.3390/cancers13061388] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
163 Heudobler D, Schulz C, Fischer JR, Staib P, Wehler T, Südhoff T, Schichtl T, Wilke J, Hahn J, Lüke F, Vogelhuber M, Klobuch S, Pukrop T, Herr W, Held S, Beckers K, Bouche G, Reichle A. A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Front Pharmacol 2021;12:599598. [PMID: 33796020 DOI: 10.3389/fphar.2021.599598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
164 Chou A, Chou SH, Liu YW. Thoracoscopic intrapericardial lingular segmentectomy for advanced lung cancer following immunotherapy. Thorac Cancer 2021;12:1461-4. [PMID: 33724695 DOI: 10.1111/1759-7714.13938] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Mayor Ibarguren A, Enrique EA, Diana PL, Ana C, Pedro HP. Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series. JAAD Case Rep 2021;11:84-9. [PMID: 33948464 DOI: 10.1016/j.jdcr.2021.03.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
166 Indini A, Rijavec E, Ghidini M, Tomasello G, Cattaneo M, Barbin F, Bareggi C, Galassi B, Gambini D, Grossi F. Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. Int J Mol Sci 2021;22:2628. [PMID: 33807855 DOI: 10.3390/ijms22052628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
167 Yuan H, Liu J, Zhang J. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. Molecules 2021;26:1392. [PMID: 33807509 DOI: 10.3390/molecules26051392] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
168 Hisanaga K, Uchino H, Kakisu N, Miyagi M, Yoshikawa F, Sato G, Isobe K, Kishi K, Homma S, Hirose T. Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan. Diabetes Metab Syndr Obes 2021;14:773-81. [PMID: 33654416 DOI: 10.2147/DMSO.S289446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
169 Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal BH, Dy GK, Ernstoff MS, Ito F. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun 2021;12:1402. [PMID: 33658501 DOI: 10.1038/s41467-021-21619-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 19.5] [Reference Citation Analysis]
170 Philippe É, Barnier A, Menguy J, Robinet G, Quéré G, Couturaud F, Descourt R. Henoch-Schönlein Purpura Associated with Lung Cancer: When Paraneoplastic Manifestations Impede Oncological Management. Case Reports Immunol 2021;2021:8847017. [PMID: 33628542 DOI: 10.1155/2021/8847017] [Reference Citation Analysis]
171 Yirgin IK, Erturk SM, Dogan I, Vatansever S. Are radiologists ready to evaluate true response to immunotherapy? Insights Imaging 2021;12:29. [PMID: 33625595 DOI: 10.1186/s13244-021-00968-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Jiang T, Luo Y, Wang B. Almonertinib-induced interstitial lung disease: A case report. Medicine (Baltimore) 2021;100:e24393. [PMID: 33546082 DOI: 10.1097/MD.0000000000024393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
173 Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen L, Zhou J. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Ther Adv Med Oncol 2021;13:1758835921992968. [PMID: 33643442 DOI: 10.1177/1758835921992968] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
174 Machado-Rugolo J, Gutierrez Prieto T, Fabro AT, Parra Cuentas ER, Sá VK, Baldavira CM, Rainho CA, Castelli EC, Farhat C, Takagaki TY, Nagai MA, Capelozzi VL. Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort. Pharmgenomics Pers Med 2021;14:239-52. [PMID: 33623414 DOI: 10.2147/PGPM.S286717] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Grambozov B, Wass R, Stana M, Gerum S, Karner J, Fastner G, Studnicka M, Sedlmayer F, Zehentmayr F. Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single-center retrospective analysis. Thorac Cancer 2021;12:1162-70. [PMID: 33586228 DOI: 10.1111/1759-7714.13884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
176 Zhang X, Zeng L, Li Y, Xu Q, Yang H, Lizaso A, Mao X, Jin R, Zeng Y, Li Q, Wang J, Li Y, Zhang Y, Yang N. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunol Immunother 2021;70:2517-28. [PMID: 33566148 DOI: 10.1007/s00262-021-02869-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
177 Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. J Cancer Res Clin Oncol 2021;147:2459-69. [PMID: 33523301 DOI: 10.1007/s00432-021-03527-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Man J, Millican J, Mulvey A, Gebski V, Hui R. Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. JNCI Cancer Spectr 2021;5:pkab012. [PMID: 34084999 DOI: 10.1093/jncics/pkab012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
179 Zhou Y, Yu F, Zhao Y, Zeng Y, Yang X, Chu L, Chu X, Li Y, Zou L, Guo T, Zhu Z, Ni J. A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player. Transl Lung Cancer Res 2020;9:2479-93. [PMID: 33489808 DOI: 10.21037/tlcr-20-1145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
180 Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Yamamoto Ramos M, Mota-Vega B, Carmona A, Peralta Álvarez MP, Bautista Y, Aldaco F, Gerson R, Rolfo C, Rosell R. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. JAMA Oncol 2020;6:856-64. [PMID: 32271354 DOI: 10.1001/jamaoncol.2020.0409] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 26.0] [Reference Citation Analysis]
181 Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol 2021;39:723-33. [PMID: 33449799 DOI: 10.1200/JCO.20.01605] [Cited by in Crossref: 125] [Cited by in F6Publishing: 141] [Article Influence: 62.5] [Reference Citation Analysis]
182 Bae JH, Baek YH, Lee JE, Song I, Lee JH, Shin JY. Machine Learning for Detection of Safety Signals From Spontaneous Reporting System Data: Example of Nivolumab and Docetaxel. Front Pharmacol 2020;11:602365. [PMID: 33628176 DOI: 10.3389/fphar.2020.602365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
183 Saka H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Horinouchi H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Yada N, Tamura T. Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies. Jpn J Clin Oncol 2021;51:106-13. [PMID: 33020837 DOI: 10.1093/jjco/hyaa157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Zhang M, Rodrigues AJ, Pollom EL, Gibbs IC, Soltys SG, Hancock SL, Neal JW, Padda SK, Ramchandran KJ, Wakelee HA, Chang SD, Lim M, Hayden Gephart M, Li G. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. J Neurooncol 2021;152:125-34. [PMID: 33415659 DOI: 10.1007/s11060-020-03686-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
185 Bezel P, Valaperti A, Steiner U, Scholtze D, Wieser S, Vonow-Eisenring M, Widmer A, Kowalski B, Kohler M, Franzen DP. Evaluation of cytokines in the tumor microenvironment of lung cancer using bronchoalveolar lavage fluid analysis. Cancer Immunol Immunother 2021;70:1867-76. [PMID: 33394095 DOI: 10.1007/s00262-020-02798-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
186 Ishihara M, Ochiai R, Haruyama T, Sakamoto T, Tanzawa S, Honda T, Ota S, Ichikawa Y, Ishida T, Watanabe K, Seki N. Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2021;10:221-32. [PMID: 33569306 DOI: 10.21037/tlcr-20-777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
187 Reguart N, Reyes R, Department of Medical Oncology, Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain, Department of Medical Oncology, Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib. Oncology & Haematology 2021;17:36. [DOI: 10.17925/ohr.2021.17.1.36] [Reference Citation Analysis]
188 Lopes C, Morgado S, Plácido AI, Roque F, Morgado M. Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management. SN Compr Clin Med 2021;3:84-94. [DOI: 10.1007/s42399-020-00670-w] [Reference Citation Analysis]
189 Izmailov A, Nasretdinov A, Sultanbaev A, Sakaeva D, Menshikov K, Sultanbaeva N, Musin S. The role of second-generation EGFR inhibitors in lung cancer therapy in the realities of modern clinical practice. Onkol Z im P A Gercena 2021;10:75. [DOI: 10.17116/onkolog20211004175] [Reference Citation Analysis]
190 Kulkarni P, Mehta P, Shriyan B, Gawit K, Gota V, Ghante M. Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics. Immunotherapy – A Novel Facet of Modern Therapeutics 2021. [DOI: 10.1007/978-981-15-9038-2_9] [Reference Citation Analysis]
191 Gupta VG, Rangaraju RR, Abbas W, Bajpai P, Khetrapal R. Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. South Asian J Cancer 2019;8:65-8. [PMID: 30766859 DOI: 10.4103/sajc.sajc_167_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
192 Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M; French Network of Regional Pharmacovigilance Centers. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer 2020;8:e001622. [PMID: 33428586 DOI: 10.1136/jitc-2020-001622] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
193 Wang L, Liu Y, Liu H, Tian H, Wang Y, Zhang G, Lei Y, Xue L, Zheng B, Fan T, Zheng Y, Tan F, Xue Q, Gao S, Li C, He J. The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors. Aging (Albany NY) 2020;13:1383-409. [PMID: 33472175 DOI: 10.18632/aging.202355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
194 Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, Molina-Pinelo S, Bernabé-Caro R. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers (Basel) 2020;12:E3729. [PMID: 33322522 DOI: 10.3390/cancers12123729] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
195 von Itzstein MS, Gonugunta AS, Mayo HG, Minna JD, Gerber DE. Immunotherapy Use in Patients With Lung Cancer and Comorbidities. Cancer J 2020;26:525-36. [PMID: 33298724 DOI: 10.1097/PPO.0000000000000484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
196 Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer 2020;20:1185. [PMID: 33272262 DOI: 10.1186/s12885-020-07690-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 35] [Article Influence: 8.7] [Reference Citation Analysis]
197 Yu G, Shen Y, Xu X, Zhong F. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis. PLoS One 2020;15:e0242982. [PMID: 33253313 DOI: 10.1371/journal.pone.0242982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
198 Buja A, Rivera M, De Polo A, Brino ED, Marchetti M, Scioni M, Pasello G, Bortolami A, Rebba V, Schiavon M, Calabrese F, Mandoliti G, Baldo V, Conte P. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. Thorac Cancer 2021;12:13-20. [PMID: 33219738 DOI: 10.1111/1759-7714.13616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
199 Lin X, Wang L, Xie X, Qin Y, Xie Z, Ouyang M, Zhou C. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma. Front Mol Biosci 2020;7:602328. [PMID: 33330629 DOI: 10.3389/fmolb.2020.602328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
200 Kubeček O, Kopecký J. Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. Onkologie 2020;14:199-204. [DOI: 10.36290/xon.2020.074] [Reference Citation Analysis]
201 Maciá S. Mesothelioma, a Review of Current Guidelines. Mesothelioma 2020. [DOI: 10.5772/intechopen.93569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
202 Yan J, Wu X, Yu J, Zhu Y, Cang S. Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis. Front Oncol 2020;10:570654. [PMID: 33240814 DOI: 10.3389/fonc.2020.570654] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
203 Tang SQ, Tang LL, Mao YP, Li WF, Chen L, Zhang Y, Guo Y, Liu Q, Sun Y, Xu C, Ma J. The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. Cancer Res Treat 2021;53:339-54. [PMID: 33171025 DOI: 10.4143/crt.2020.790] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
204 Wu CE, Chang CF, Kou-Sheng L, Chiang J, Lee SW, Chiu YC. PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC. Anal Cell Pathol (Amst) 2020;2020:3286139. [PMID: 33204603 DOI: 10.1155/2020/3286139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Cvetkovic L, Régis C, Richard C, Derosa L, Leblond A, Malo J, Messaoudene M, Desilets A, Belkaid W, Elkrief A, Routy B, Juneau D. Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging 2021;48:1550-9. [PMID: 33128571 DOI: 10.1007/s00259-020-05081-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
206 Ding XC, Wang LL, Zhu YF, Li YD, Nie SL, Yang J, Liang H, Weichselbaum RR, Yu JM, Hu M. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. Front Immunol 2020;11:580335. [PMID: 33224142 DOI: 10.3389/fimmu.2020.580335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
207 Li C, Liu J, Xie Z, Zhu F, Cheng B, Liang H, Li J, Xiong S, Chen Z, Liu Z, Zhao Y, Ou L, Zhong R, Wang W, Huang J, Sun J, Zhang C, Weng L, He J, Liang W, Pan Z. PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. Ther Adv Med Oncol 2020;12:1758835920965840. [PMID: 33403009 DOI: 10.1177/1758835920965840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
208 Xu Y, Fu Y, Zhu B, Wang J, Zhang B. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front Immunol 2020;11:2023. [PMID: 33123120 DOI: 10.3389/fimmu.2020.02023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
209 Shieh AC, Guler E, Pfau D, Radzinsky E, Smith DA, Hoimes C, Ramaiya NH, Tirumani SH. Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. Abdom Radiol (NY) 2020;45:3028-35. [PMID: 31754740 DOI: 10.1007/s00261-019-02334-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
210 Bishay K, Tandon P, Bourassa-Blanchette S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Curr Oncol. 2020;27:e486-e494. [PMID: 33173388 DOI: 10.3747/co.27.6251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
211 Schouten RD, Egberink L, Muller M, De Gooijer CJ, van Werkhoven E, van den Heuvel MM, Baas P. Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care. Transl Lung Cancer Res 2020;9:1736-48. [PMID: 33209597 DOI: 10.21037/tlcr-19-698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
212 Xia WY, Feng W, Zhang CC, Shen YJ, Zhang Q, Yu W, Cai XW, Fu XL. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. Transl Lung Cancer Res 2020;9:2120-36. [PMID: 33209631 DOI: 10.21037/tlcr-20-827] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
213 Zhou C, Wang J, Bu H, Wang B, Han B, Lu Y, Wang Z, Zhu B, Wang Z, Song Q, Ren S, Lin D, He Y, Hu X, Zhao H, Qin S. [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)]. Zhongguo Fei Ai Za Zhi 2020;23:65-76. [PMID: 32093450 DOI: 10.3779/j.issn.1009-3419.2020.02.01] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
214 Teng F, Li M, Yu J. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications. BMC Med 2020;18:275. [PMID: 32943072 DOI: 10.1186/s12916-020-01718-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
215 Chen Y, Li X, Liu G, Chen S, Xu M, Song L, Wang Y. ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC. Front Oncol 2020;10:1706. [PMID: 33014846 DOI: 10.3389/fonc.2020.01706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
216 Hu G, Sun N, Jiang J, Chen X. Establishment of a 5-gene risk model related to regulatory T cells for predicting gastric cancer prognosis. Cancer Cell Int 2020;20:433. [PMID: 32908454 DOI: 10.1186/s12935-020-01502-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
217 Ding H, Xin W, Tong Y, Sun J, Xu G, Ye Z, Rao Y. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. PLoS One 2020;15:e0238536. [PMID: 32877435 DOI: 10.1371/journal.pone.0238536] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
218 Correale P, Saladino RE, Giannarelli D, Sergi A, Mazzei MA, Bianco G, Giannicola R, Iuliano E, Forte IM, Calandruccio ND, Falzea AC, Strangio A, Nardone V, Pastina P, Tini P, Luce A, Caraglia M, Caracciolo D, Mutti L, Tassone P, Pirtoli L, Giordano A, Tagliaferri P. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. Cells 2020;9:E1964. [PMID: 32854442 DOI: 10.3390/cells9091964] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
219 Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clin Med Insights Oncol 2020;14:1179554920951358. [PMID: 32884390 DOI: 10.1177/1179554920951358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
220 Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020;383:640-9. [PMID: 32786189 DOI: 10.1056/NEJMoa1916623] [Cited by in Crossref: 422] [Cited by in F6Publishing: 464] [Article Influence: 140.7] [Reference Citation Analysis]
221 Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Sci Rep 2020;10:13773. [PMID: 32792640 DOI: 10.1038/s41598-020-70743-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
222 Sun D, Tian L, Zhu Y, Wo Y, Liu Q, Liu S, Li H, Hou H. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer. Mol Med 2020;26:78. [PMID: 32791957 DOI: 10.1186/s10020-020-00208-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
223 Choi M, Kim HT, Han JY, Lee GK, Lee SH, Lim KY, Joo J, Won HJ, Lee JS, Lee Y. Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer. Cancer Res Treat 2021;53:87-92. [PMID: 32810931 DOI: 10.4143/crt.2020.741] [Reference Citation Analysis]
224 Song P, Yang D, Cui X, Wang H, Si X, Zhang X, Zhang L. NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. Cancer Manag Res 2020;12:5975-85. [PMID: 32765097 DOI: 10.2147/CMAR.S257967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
225 Ruiz-Patiño A, Barrón F, Cardona AF, Corrales L, Mas L, Martín C, Zatarain-Barrón ZL, Recondo G, Ricaurte L, Rojas L, Archila P, Rodríguez J, Sotelo C, Viola L, Vargas C, Carranza H, Otero J, Pino LE, Rolfo C, Rosell R, Arrieta O; CLICaP. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP). Thorac Cancer 2020;11:2552-60. [PMID: 32705787 DOI: 10.1111/1759-7714.13573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
226 Gomes F, Wong M, Battisti NML, Kordbacheh T, Kiderlen M, Greystoke A, Luciani A. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. Br J Cancer 2020;123:874-84. [PMID: 32694695 DOI: 10.1038/s41416-020-0986-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
227 Shan Q, Li Z, Lin J, Guo J, Han X, Song X, Wang H, Wang Z. Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study. J Oncol 2020;2020:4784701. [PMID: 32695165 DOI: 10.1155/2020/4784701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
228 Botticelli A, Mezi S, Pomati G, Cerbelli B, Cerbelli E, Roberto M, Giusti R, Cortellini A, Lionetto L, Scagnoli S, Zizzari IG, Nuti M, Simmaco M, Marchetti P. Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. Front Immunol 2020;11:1243. [PMID: 32733441 DOI: 10.3389/fimmu.2020.01243] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
229 Guo L, Wei R, Lin Y, Kwok HF. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective. Front Immunol 2020;11:1508. [PMID: 32733486 DOI: 10.3389/fimmu.2020.01508] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
230 Wang Y, Zhao N, Zhang X, Li Z, Liang Z, Yang J, Liu X, Wu Y, Chen K, Gao Y, Yin Z, Lin X, Zhou H, Tian D, Cao Y, Hao J. Bibliometrics Analysis of Butyrophilins as Immune Regulators [1992-2019] and Implications for Cancer Prognosis. Front Immunol 2020;11:1187. [PMID: 32695099 DOI: 10.3389/fimmu.2020.01187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
231 Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J Clin Med 2020;9:E1870. [PMID: 32549358 DOI: 10.3390/jcm9061870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
232 Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal BH, Dy GK, Ernstoff MS, Ito F. A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors.. [DOI: 10.1101/2020.06.13.095844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
233 Tamminga M, Hiltermann TJN, Schuuring E, Timens W, Fehrmann RS, Groen HJ. Immune microenvironment composition in non-small cell lung cancer and its association with survival. Clin Transl Immunology 2020;9:e1142. [PMID: 32547744 DOI: 10.1002/cti2.1142] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 17.3] [Reference Citation Analysis]
234 Gorospe L, Pacios-blanco RE, Garrido-lópez P. The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. Archivos de Bronconeumología (English Edition) 2020;56:380-389. [DOI: 10.1016/j.arbr.2020.04.003] [Reference Citation Analysis]
235 Kanda S, Ohe Y, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Yamamoto T, Tamura T. Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Cancer Sci 2020;111:1933-42. [PMID: 32277531 DOI: 10.1111/cas.14410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
236 Chen M, Li Q, Xu Y, Zhao J, Zhang L, Wei L, Zhong W, Wang M. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. Thorac Cancer 2020;11:1955-62. [PMID: 32468726 DOI: 10.1111/1759-7714.13488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
237 Zhang C, Fan Y, Che X, Zhang M, Li Z, Li C, Wang S, Wen T, Hou K, Shao X, Liu Y, Qu X. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. Front Oncol 2020;10:760. [PMID: 32528882 DOI: 10.3389/fonc.2020.00760] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
238 Tamminga M, Groen HJ. Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer. Applied Sciences 2020;10:3704. [DOI: 10.3390/app10113704] [Reference Citation Analysis]
239 Pinheiro FD, Teixeira AF, de Brito BB, da Silva FAF, Santos MLC, de Melo FF. Immunotherapy – new perspective in lung cancer. World J Clin Oncol 2020; 11(5): 250-259 [PMID: 32728528 DOI: 10.5306/wjco.v11.i5.250] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
240 Lu Y, Song Y, Xu Y, Ou N, Liang Z, Hu R, Zhang W, Kang J, Wang X, Liu L, Yang Y, Liu X. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. Transl Androl Urol 2020;9:367-81. [PMID: 32420142 DOI: 10.21037/tau.2020.01.21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
241 Geier M, Descourt R, Corre R, Léveiller G, Lamy R, Goarant É, Bizec JL, Bernier C, Quéré G, Amrane K, Gaye E, Lucia F, Burte E, Chouaid C, Robinet G. Duration of nivolumab for pretreated, advanced non-small-cell lung cancer. Cancer Med 2020;9:6923-32. [PMID: 32412157 DOI: 10.1002/cam4.3120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
242 Liu Y, Zhang J, Yin Z, Zhu X, Xue L, Cao B. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol. Thorac Cancer 2020;11:2023-30. [PMID: 32379397 DOI: 10.1111/1759-7714.13463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
243 Zhao X, Wangmo D, Robertson M, Subramanian S. Acquired Resistance to Immune Checkpoint Blockade Therapies. Cancers (Basel) 2020;12:E1161. [PMID: 32380703 DOI: 10.3390/cancers12051161] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
244 Rossi G, Russo A, Tagliamento M, Tuzi A, Nigro O, Vallome G, Sini C, Grassi M, Dal Bello MG, Coco S, Longo L, Zullo L, Tanda ET, Dellepiane C, Pronzato P, Genova C. Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers (Basel) 2020;12:E1125. [PMID: 32365882 DOI: 10.3390/cancers12051125] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
245 Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther 2020;27:841-53. [PMID: 32341410 DOI: 10.1038/s41417-020-0174-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
246 Liu Y, Zhang T, Gao Y, Qu Y, Lu B, Zhang H, Wang Q, Li J, Hu F, Li B. [A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice]. Zhongguo Fei Ai Za Zhi 2019;22:687-95. [PMID: 31771737 DOI: 10.3779/j.issn.1009-3419.2019.11.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
247 Cathcart-Rake EJ, Sangaralingham LR, Henk HJ, Shah ND, Riaz IB, Mansfield AS. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. Clin Lung Cancer 2020;21:421-427.e2. [PMID: 32446852 DOI: 10.1016/j.cllc.2020.04.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
248 Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, Garcia-Granda MJ, Blanco E, Vera R, Kochan G, Escors D. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? Front Pharmacol 2020;11:441. [PMID: 32317979 DOI: 10.3389/fphar.2020.00441] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
249 Dawe DE, Harlos CH, Juergens RA. Immuno-oncology-the new paradigm of lung cancer treatment. Curr Oncol 2020;27:S78-86. [PMID: 32368177 DOI: 10.3747/co.27.5183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
250 Levin AS. CORR Insights®: External Validation of PATHFx Version 3.0 in Patients Treated Surgically and Nonsurgically for Symptomatic Skeletal Metastases. Clin Orthop Relat Res 2020;478:819-21. [PMID: 32195762 DOI: 10.1097/CORR.0000000000001148] [Reference Citation Analysis]
251 Berghmans T, Durieux V, Hendriks LEL, Dingemans AM. Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. Front Med (Lausanne) 2020;7:90. [PMID: 32266275 DOI: 10.3389/fmed.2020.00090] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
252 Ohmura H, Yamaguchi K, Hanamura F, Ito M, Makiyama A, Uchino K, Shimokawa H, Tamura S, Esaki T, Mitsugi K, Shibata Y, Oda H, Tsuchihashi K, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. Br J Cancer 2020;122:1507-17. [PMID: 32203221 DOI: 10.1038/s41416-020-0810-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
253 Cheng Y, Wang T, Lv X, Li R, Yuan L, Shen J, Li Y, Yan T, Liu B, Wang L. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer. Cancer Manag Res 2020;12:2069-78. [PMID: 32256114 DOI: 10.2147/CMAR.S245425] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
254 Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, Vögeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, Niegisch G, Gaisa NT; German Study Group of Bladder Cancer (DFBK e.V.). Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer 2020;20:230. [PMID: 32188412 DOI: 10.1186/s12885-020-06727-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
255 Samaranayake CB, McCaffrey E, Coucher J, Lehman M, Mai GT, Murphy MA. Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study. ERJ Open Res 2020;6:00189-2019. [PMID: 32166087 DOI: 10.1183/23120541.00189-2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
256 Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH, Lee KH, Lin CC, Flor MJ, Di Nicola M, Alvarez RM, Dussault I, Helwig C, Ojalvo LS, Gulley JL, Cho BC. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol 2020;15:1210-22. [PMID: 32173464 DOI: 10.1016/j.jtho.2020.03.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 65] [Article Influence: 18.3] [Reference Citation Analysis]
257 Yang W, Men P, Xue H, Jiang M, Luo Q. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:197. [PMID: 32211312 DOI: 10.3389/fonc.2020.00197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
258 Liang H, Xu Y, Chen M, Zhong W, Wang M, Zhao J. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thorac Cancer 2020;11:1068-75. [PMID: 32129934 DOI: 10.1111/1759-7714.13367] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
259 Xia L, Liu Y, Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 2019;24:S31-41. [PMID: 30819829 DOI: 10.1634/theoncologist.2019-IO-S1-s05] [Cited by in Crossref: 102] [Cited by in F6Publishing: 133] [Article Influence: 34.0] [Reference Citation Analysis]
260 Refae S, Gal J, Brest P, Giacchero D, Borchiellini D, Ebran N, Peyrade F, Guigay J, Milano G, Saada-Bouzid E. Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. Sci Rep 2020;10:3565. [PMID: 32107407 DOI: 10.1038/s41598-020-60437-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
261 Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 2020; 12(2): 173-181 [PMID: 32104548 DOI: 10.4251/wjgo.v12.i2.173] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 98] [Article Influence: 33.3] [Reference Citation Analysis]
262 Fukui T, Hosotani S, Soda I, Ozawa T, Kusuhara S, Kakegawa MI, Kasajima M, Hiyoshi Y, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Ishiyama H, Naoki K. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab. Thorac Cancer 2020;11:1005-14. [PMID: 32057187 DOI: 10.1111/1759-7714.13357] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
263 Toyozawa R, Haratake N, Toyokawa G, Matsubara T, Takamori S, Miura N, Yamaguchi M, Takenoyama M, Seto T. Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC. JTO Clin Res Rep 2020;1:100012. [PMID: 34589914 DOI: 10.1016/j.jtocrr.2020.100012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
264 Byeon S, Cho JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Med 2020;9:2352-62. [PMID: 32027780 DOI: 10.1002/cam4.2868] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
265 Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. Cancer Med 2020;9:2309-16. [PMID: 32022459 DOI: 10.1002/cam4.2806] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
266 Arasanz H, Zuazo M, Bocanegra A, Gato M, Martínez-Aguillo M, Morilla I, Fernández G, Hernández B, López P, Alberdi N, Hernández C, Chocarro L, Teijeira L, Vera R, Kochan G, Escors D. Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers (Basel) 2020;12:E344. [PMID: 32033028 DOI: 10.3390/cancers12020344] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
267 Elkrief A, Joubert P, Florescu M, Tehfe M, Blais N, Routy B. Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020. Curr Oncol 2020;27:52-60. [PMID: 32218661 DOI: 10.3747/co.27.5953] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
268 Kunimasa K, Goto T. Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. Int J Mol Sci 2020;21:E597. [PMID: 31963413 DOI: 10.3390/ijms21020597] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
269 Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M, Morihiro T, Kubota T, Aoyama K, Kikuchi S, Nishizaki M, Kagawa S, Tazawa H, Mizuguchi H, Urata Y, Fujiwara T. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Mol Ther 2020;28:794-804. [PMID: 31991110 DOI: 10.1016/j.ymthe.2020.01.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
270 Gorospe L, Pacios-Blanco RE, Garrido-López P. The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. Arch Bronconeumol (Engl Ed) 2020;56:380-9. [PMID: 31898993 DOI: 10.1016/j.arbres.2019.10.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
271 Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A. Imaging of tumour response to immunotherapy. Eur Radiol Exp 2020;4:2. [PMID: 31900689 DOI: 10.1186/s41747-019-0134-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 14.7] [Reference Citation Analysis]
272 Zhao L, Yu J, Wang J, Li H, Che J, Cao B. Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. J Cancer 2020;11:41-50. [PMID: 31892971 DOI: 10.7150/jca.32724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
273 Lee KWC, Lord SJ, Kasherman L, Marschner I, Stockler M, Gralla R, Yang JC, Mok T, Lee CK. The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. Acta Oncol 2020;59:96-100. [PMID: 31552770 DOI: 10.1080/0284186X.2019.1670354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
274 Su Z, Zhou L, Xue J, Lu Y. Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. Chin J Cancer Res 2020;32:448-66. [PMID: 32963458 DOI: 10.21147/j.issn.1000-9604.2020.04.03] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
275 Rossi G, Russo A, Tagliamento M, Tuzi A, Nigro O, Vollome G, Sini C, Grassi M, Dal bello M, Coco S, Longo L, Zullo L, Tanda E, Dellepiane C, Pronzato P, Genova C. Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. Kompass Pneumol 2020;8:300-317. [DOI: 10.1159/000511444] [Reference Citation Analysis]
276 Paudel KR, Panth N, Pangeni R, Awasthi R, Chawla V, Mehta M, Tambuwala MM, Hansbro PM. Targeting lung cancer using advanced drug delivery systems. Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems 2020. [DOI: 10.1016/b978-0-12-820658-4.00023-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
277 Paliogiannis P, Scano V, Mangoni AA, Cossu A, Palmieri G. Long Noncoding RNAs in Non-Small Cell Lung Cancer: State of the Art. RNA Technologies 2020. [DOI: 10.1007/978-3-030-44743-4_12] [Reference Citation Analysis]
278 Baseri B, Samra B, Tam E, Chiu E, Leaf A. An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Case Rep Oncol Med 2019;2019:1816472. [PMID: 31885970 DOI: 10.1155/2019/1816472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
279 Adachi Y, Tamiya A, Taniguchi Y, Enomoto T, Azuma K, Kouno S, Inagaki Y, Saijo N, Okishio K, Atagi S. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. Cancer Med 2020;9:1383-91. [PMID: 31880861 DOI: 10.1002/cam4.2807] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
280 Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019;5:393-401. [PMID: 30676622 DOI: 10.1001/jamaoncol.2018.6258] [Cited by in Crossref: 204] [Cited by in F6Publishing: 216] [Article Influence: 51.0] [Reference Citation Analysis]
281 Nardone V, Tini P, Pastina P, Botta C, Reginelli A, Carbone SF, Giannicola R, Calabrese G, Tebala C, Guida C, Giudice A, Barbieri V, Tassone P, Tagliaferri P, Cappabianca S, Capasso R, Luce A, Caraglia M, Mazzei MA, Pirtoli L, Correale P. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. Oncol Lett 2020;19:1559-66. [PMID: 31966081 DOI: 10.3892/ol.2019.11220] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
282 Ruiz-Patiño A, Arrieta O, Cardona AF, Martín C, Raez LE, Zatarain-Barrón ZL, Barrón F, Ricaurte L, Bravo-Garzón MA, Mas L, Corrales L, Rojas L, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Rizzo M, Ruiz R, Rolfo C, Archila P, Rodríguez J, Sotelo C, Vargas C, Carranza H, Otero J, Pino LE, Ortíz C, Laguado P, Rosell R; CLICaP. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thorac Cancer 2020;11:353-61. [PMID: 31828967 DOI: 10.1111/1759-7714.13272] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
283 Zhang PF, Pei X, Li KS, Jin LN, Wang F, Wu J, Zhang XM. Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer 2019;18:179. [PMID: 31815619 DOI: 10.1186/s12943-019-1111-2] [Cited by in Crossref: 107] [Cited by in F6Publishing: 122] [Article Influence: 26.8] [Reference Citation Analysis]
284 Laktionov KK, Sarantseva KA, Yudin DI, Breder VV, Reutova EV, Laktionov KP. Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center. Medicinskij sovet 2019. [DOI: 10.21518/2079-701x-2019-19-16-21] [Reference Citation Analysis]
285 Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. Cancers (Basel) 2019;11:E1954. [PMID: 31817541 DOI: 10.3390/cancers11121954] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
286 Benitez JC, Remon J, Besse B. CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy? Transl Lung Cancer Res 2019;8:S464-7. [PMID: 32038939 DOI: 10.21037/tlcr.2019.12.26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
287 Steffen McLouth LE, Lycan TW Jr, Levine BJ, Gabbard J, Ruiz J, Farris M, Grant SC, Pajewski NM, Weaver KE, Petty WJ. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. Clin Lung Cancer 2020;21:255-263.e4. [PMID: 31917067 DOI: 10.1016/j.cllc.2019.11.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
288 Zhang D, Huang J, Zhang C, Guan Y, Guo Q. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:369-79. [PMID: 31196371 DOI: 10.3779/j.issn.1009-3419.2019.06.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
289 Kimura H, Araya T, Yoneda T, Shirasaki H, Kurokawa K, Sakai T, Koba H, Tambo Y, Nishikawa S, Sone T, Kasahara K. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. Cancer Commun (Lond) 2019;39:78. [PMID: 31753015 DOI: 10.1186/s40880-019-0423-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
290 Funazo TY, Nomizo T, Ozasa H, Tsuji T, Yasuda Y, Yoshida H, Sakamori Y, Nagai H, Hirai T, Kim YH. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Sci Rep 2019;9:17085. [PMID: 31745135 DOI: 10.1038/s41598-019-53327-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
291 Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, Shin JI, Gamerith G. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1798. [PMID: 31731749 DOI: 10.3390/cancers11111798] [Cited by in Crossref: 59] [Cited by in F6Publishing: 68] [Article Influence: 14.8] [Reference Citation Analysis]
292 Nishiyama N, Honda T, Sema M, Kawahara T, Jin Y, Natsume I, Chiaki T, Yamashita T, Tsukada Y, Taki R, Miyashita Y, Saito K, Tateishi T, Sakashita H, Miyazaki Y. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease. Int J Clin Oncol 2020;25:282-91. [PMID: 31720993 DOI: 10.1007/s10147-019-01576-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
293 Carbone C, Piro G, Di Noia V, D'Argento E, Vita E, Ferrara MG, Pilotto S, Milella M, Cammarota G, Gasbarrini A, Tortora G, Bria E. Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators Inflamm 2019;2019:7652014. [PMID: 31827379 DOI: 10.1155/2019/7652014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
294 Lu D, Ni Z, Liu X, Feng S, Dong X, Shi X, Zhai J, Mai S, Jiang J, Wang Z, Wu H, Cai K. Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. J Immunol Res 2019;2019:1919082. [PMID: 31781673 DOI: 10.1155/2019/1919082] [Cited by in Crossref: 56] [Cited by in F6Publishing: 66] [Article Influence: 14.0] [Reference Citation Analysis]
295 Dong J, Zhu D, Tang X, Qiu X, Lu D, Li B, Lin D, Zhou Q. Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I-III Non-small Cell Lung Cancer Patients. Front Oncol 2019;9:1139. [PMID: 31737568 DOI: 10.3389/fonc.2019.01139] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
296 Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 2019;36:444-457.e7. [PMID: 31588020 DOI: 10.1016/j.ccell.2019.09.001] [Cited by in Crossref: 88] [Cited by in F6Publishing: 96] [Article Influence: 22.0] [Reference Citation Analysis]
297 Maruhashi R, Eguchi H, Akizuki R, Hamada S, Furuta T, Matsunaga T, Endo S, Ichihara K, Ikari A. Chrysin enhances anticancer drug-induced toxicity mediated by the reduction of claudin-1 and 11 expression in a spheroid culture model of lung squamous cell carcinoma cells. Sci Rep 2019;9:13753. [PMID: 31551535 DOI: 10.1038/s41598-019-50276-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
298 Arias Ron D, Labandeira CM, Areses Manrique MC, Sampedro Domarco P, Abdulkader I, García-Mata J, Rolfo C, González-Rivas D, Fírvida JL. Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report. Front Oncol 2019;9:819. [PMID: 31552167 DOI: 10.3389/fonc.2019.00819] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
299 O’dea D, Lyng FM, Nicholson S, O'connell F, Maguire A, Malkin A. Recent advances in the vibrational spectroscopic diagnosis of non-small cell lung cancer. Vibrational Spectroscopy 2019;104:102946. [DOI: 10.1016/j.vibspec.2019.102946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
300 Qiu Z, Chen Z, Zhang C, Zhong W. Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Exp Hematol Oncol 2019;8:19. [PMID: 31463163 DOI: 10.1186/s40164-019-0143-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
301 Liang H, Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag Res 2019;11:7707-19. [PMID: 31616186 DOI: 10.2147/CMAR.S212238] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
302 Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeño J, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S, Crinò L, Planchard D, Butts C, Drilon A, Wojcik-Tomaszewska J, Otterson GA, Agrawal S, Li A, Penrod JR, Brahmer J. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019;20:1395-408. [PMID: 31422028 DOI: 10.1016/S1470-2045(19)30407-3] [Cited by in Crossref: 159] [Cited by in F6Publishing: 172] [Article Influence: 39.8] [Reference Citation Analysis]
303 Martinez-Morilla S, McGuire J, Gaule P, Moore L, Acs B, Cougot D, Gown AM, Yaziji H, Wang WL, Cartun RW, Hornick JL, Sholl LM, Qiu J, Mino-Kenudson M, Yi ES, Beasley MB, Merrick DT, Ambaye AB, Zhang ZJ, Walker J, Rimm DL. Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. Lab Invest 2020;100:4-15. [PMID: 31409885 DOI: 10.1038/s41374-019-0295-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
304 Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer 2019;19:495-509. [PMID: 31406302 DOI: 10.1038/s41568-019-0179-8] [Cited by in Crossref: 316] [Cited by in F6Publishing: 345] [Article Influence: 79.0] [Reference Citation Analysis]
305 Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Fellows KM, Francis JM, Saller JJ, Mesa T, Zhang C, Yoder S, DeNicola GM, Beg AA, Boyle TA, Teer JK, Ann Chen Y, Koomen JM, Eschrich SA, Haura EB. Proteogenomic landscape of squamous cell lung cancer. Nat Commun 2019;10:3578. [PMID: 31395880 DOI: 10.1038/s41467-019-11452-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
306 Dong J, Zhu D, Tang X, Lu D, Qiu X, Li B, Lin D, Li L, Liu J, Zhou Q. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. PLoS One 2019;14:e0220306. [PMID: 31348821 DOI: 10.1371/journal.pone.0220306] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
307 Sun S, Jin S, Guo R. [Role of STAT3 in Resistance of Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:457-63. [PMID: 31315785 DOI: 10.3779/j.issn.1009-3419.2019.07.08] [Reference Citation Analysis]
308 Gaffney SG, Perry EB, Chen PM, Greenstein A, Kaech SM, Townsend JP. The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget 2019;10:4532-45. [PMID: 31360302 DOI: 10.18632/oncotarget.27027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
309 Qiu Y, Jiang J, Zhang M, Qin Y. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. Oncol Lett 2019;18:161-8. [PMID: 31289485 DOI: 10.3892/ol.2019.10302] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
310 Tamminga M, de Wit S, Hiltermann TJN, Timens W, Schuuring E, Terstappen LWMM, Groen HJM. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. J Immunother Cancer 2019;7:173. [PMID: 31291995 DOI: 10.1186/s40425-019-0649-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
311 Alama A, Coco S, Genova C, Rossi G, Fontana V, Tagliamento M, Giovanna Dal Bello M, Rosa A, Boccardo S, Rijavec E, Biello F, Longo L, Cavalieri Z, Bruzzo C, Grossi F. Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. J Clin Med 2019;8:E1011. [PMID: 31295929 DOI: 10.3390/jcm8071011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
312 Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. JAMA Netw Open 2019;2:e196879. [PMID: 31290993 DOI: 10.1001/jamanetworkopen.2019.6879] [Cited by in Crossref: 105] [Cited by in F6Publishing: 115] [Article Influence: 26.3] [Reference Citation Analysis]
313 Chen DT, Schell MJ, Fulp WJ, Pettersson F, Kim S, Gray JE, Haura EB. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. Transl Cancer Res 2019;8:S404-20. [PMID: 31456910 DOI: 10.21037/tcr.2019.05.17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
314 Lv Y, Huang Z, Lin Y, Fang Y, Chen Z, Pan L, Zhang Y, Xu Z. MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma. Oncoimmunology. 2019;8:e1629260. [PMID: 31646073 DOI: 10.1080/2162402x.2019.1629260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
315 Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, Hao R, Pan J, Zhao X, Chen D, Song Y, Qi Y, Tang L, Liu Z, Gao R, Shi Y, Yang Z. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond) 2019;39:36. [PMID: 31221221 DOI: 10.1186/s40880-019-0383-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
316 Sillo TO, Beggs AD, Morton DG, Middleton G. Mechanisms of immunogenicity in colorectal cancer. Br J Surg 2019;106:1283-97. [PMID: 31216061 DOI: 10.1002/bjs.11204] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
317 Janning M, Kobus F, Babayan A, Wikman H, Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Böttcher LM, Päsler S, Gorges TM, O'Flaherty L, Hille C, Joosse SA, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. Cancers (Basel) 2019;11:E835. [PMID: 31212989 DOI: 10.3390/cancers11060835] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 18.3] [Reference Citation Analysis]
318 Zhu J, Zhang T, Li J, Lin J, Liang W, Huang W, Wan N, Jiang J. Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. Front Pharmacol 2019;10:673. [PMID: 31258479 DOI: 10.3389/fphar.2019.00673] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]
319 Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. EMBO Mol Med 2019;11:e10293. [PMID: 31273938 DOI: 10.15252/emmm.201910293] [Cited by in Crossref: 89] [Cited by in F6Publishing: 99] [Article Influence: 22.3] [Reference Citation Analysis]
320 Yu Y, Ma X, Zhang Y, Zhang Y, Ying J, Zhang W, Zhong Q, Zhou A, Zeng Y. Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer. J Cancer 2019;10:2754-63. [PMID: 31258783 DOI: 10.7150/jca.31755] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
321 Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8:302-16. [PMID: 31367543 DOI: 10.21037/tlcr.2019.04.12] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 13.8] [Reference Citation Analysis]
322 Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res 2019;25:5061-8. [PMID: 31113840 DOI: 10.1158/1078-0432.CCR-18-4275] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
323 Liu Y, Zhou S, Du Y, Sun L, Jiang H, Zhang B, Sun G, Wang R. Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis

]]>. CMAR 2019;Volume 11:4619-30. [DOI: 10.2147/cmar.s193394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
324 Patel A, Soneji D, Parikh P, Kumar M. Biomarkers in immuno-oncology: A review article. Int J Mol and ImmuOncol 2019;4:41-49. [DOI: 10.25259/ijmio-12-2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
325 Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, Tassone P, Tagliaferri P, Correale P. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. Mol Clin Oncol 2019;11:81-90. [PMID: 31289683 DOI: 10.3892/mco.2019.1859] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
326 Bachelier M, Dauxois J, Filleron T. Intérêt des modèles de guérison dans le cadre des essais d’immunothérapie. Revue d'Épidémiologie et de Santé Publique 2019;67:S141-S142. [DOI: 10.1016/j.respe.2019.03.004] [Reference Citation Analysis]
327 Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, Awad MM. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol (NY) 2019;44:1917-27. [PMID: 30790009 DOI: 10.1007/s00261-019-01935-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
328 Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U; Immune-Oncology YOUNG Group. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. Biomed Res Int 2019;2019:9056417. [PMID: 31179334 DOI: 10.1155/2019/9056417] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
329 Wojas-Krawczyk K, Kalinka E, Grenda A, Krawczyk P, Milanowski J. Beyond PD-L1 Markers for Lung Cancer Immunotherapy. Int J Mol Sci 2019;20:E1915. [PMID: 31003463 DOI: 10.3390/ijms20081915] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 9.3] [Reference Citation Analysis]
330 Song P, Zhang J, Zhang L. Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer. Onco Targets Ther 2019;12:2943-8. [PMID: 31114237 DOI: 10.2147/OTT.S203192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
331 Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. Oncologist 2019;24:e1165-71. [PMID: 30996007 DOI: 10.1634/theoncologist.2018-0737] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
332 Kato Y, Okuma Y, Watanabe K, Yomota M, Kawai S, Hosomi Y, Okamura T. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2019;84:351-8. [PMID: 30993397 DOI: 10.1007/s00280-019-03843-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
333 Vigliar E, Malapelle U, Bono F, Fusco N, Cortinovis D, Valtorta E, Spyridon A, Bimbatti M, Zocchi M, Piva C, Gaudioso G, Iaccarino A, Morbini P, Pagni F. The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. Biomed Res Int 2019;2019:6832909. [PMID: 31111063 DOI: 10.1155/2019/6832909] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
334 Grenda A, Nicoś M, Szczyrek M, Krawczyk P, Kucharczyk T, Jarosz B, Pankowski J, Sawicki M, Szumiło J, Bukała P, Milanowski J. MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. Oncol Lett 2019;17:5193-200. [PMID: 31186735 DOI: 10.3892/ol.2019.10207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
335 Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. Int J Mol Sci 2019;20:E1631. [PMID: 30986912 DOI: 10.3390/ijms20071631] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 9.8] [Reference Citation Analysis]
336 Caster JM, Callaghan C, Seyedin SN, Henderson K, Sun B, Wang AZ. Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy. Adv Drug Deliv Rev 2019;144:3-15. [PMID: 31330165 DOI: 10.1016/j.addr.2019.07.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
337 Liu S, Qin T, Jia Y, Li K. PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival. Front Oncol 2019;9:189. [PMID: 30972298 DOI: 10.3389/fonc.2019.00189] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
338 Kulasinghe A, Kapeleris J, Cooper C, Warkiani ME, O'Byrne K, Punyadeera C. Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets. Cancers (Basel) 2019;11:E380. [PMID: 30889898 DOI: 10.3390/cancers11030380] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
339 Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis 2018;12:1753466618794133. [PMID: 30215300 DOI: 10.1177/1753466618794133] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
340 Meindl-Beinker NM, Betge J, Gutting T, Burgermeister E, Belle S, Zhan T, Schulte N, Maenz M, Ebert MP, Haertel N. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). BMC Cancer 2019;19:231. [PMID: 30871493 DOI: 10.1186/s12885-019-5446-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
341 Song P, Zhang J, Shang C, Zhang L. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. Sci Rep 2019;9:4278. [PMID: 30862891 DOI: 10.1038/s41598-019-40748-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
342 Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res 2019;25:4592-602. [PMID: 30824587 DOI: 10.1158/1078-0432.CCR-18-1538] [Cited by in Crossref: 260] [Cited by in F6Publishing: 294] [Article Influence: 65.0] [Reference Citation Analysis]
343 Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019;5:393-401. [PMID: 30676622 DOI: 10.1001/jamaoncol.2018.6258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
344 Nakamura A, Aiba T, Kawana S, Saito R, Toi Y, Sugawara S. A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab. JJLC 2019;59:60-65. [DOI: 10.2482/haigan.59.60] [Reference Citation Analysis]
345 Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, Vaishampayan U, Weise A, Flaherty L, Jang H, Kim S, Gadgeel S. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. Anticancer Res 2019;39:781-90. [PMID: 30711957 DOI: 10.21873/anticanres.13175] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
346 Corral J, Majem M, Rodríguez-Abreu D, Carcereny E, Cortes ÁA, Llorente M, López Picazo JM, García Y, Domine M, López Criado MP. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clin Transl Oncol 2019;21:1270-9. [PMID: 30771085 DOI: 10.1007/s12094-019-02053-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
347 Kim HS, Kim JH, Han B, Choi DR. Correlation of Thyroid Transcription Factor-1 Expression with EGFR Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis. Medicina (Kaunas) 2019;55:E41. [PMID: 30736438 DOI: 10.3390/medicina55020041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
348 Park S, Kim JY, Lee JC, Kim HR, Song S, Kwon H, Ji W, Choi CM. Mobile Phone App-Based Pulmonary Rehabilitation for Chemotherapy-Treated Patients With Advanced Lung Cancer: Pilot Study. JMIR Mhealth Uhealth 2019;7:e11094. [PMID: 30714943 DOI: 10.2196/11094] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
349 Hamel-Perreault E, Mathieu D, Masson-Cote L. Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases. Curr Oncol 2019;26:e64-9. [PMID: 30853811 DOI: 10.3747/co.25.4244] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
350 Cusato J, Genova C, Tomasello C, Carrega P, Ottonello S, Pietra G, Mingari MC, Cossu I, Rijavec E, Leggieri A, Di Perri G, Dal Bello MG, Coco S, Boccardo S, Ferlazzo G, Grossi F, D'Avolio A. Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers (Basel) 2019;11:E125. [PMID: 30669662 DOI: 10.3390/cancers11010125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
351 Xu Z, Yi F, Yu D, Xu J, Wei Y, Zhang W. Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis. Cancer Med 2019;8:629-42. [PMID: 30628185 DOI: 10.1002/cam4.1966] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
352 Nandi D, Singal A, Nag A. Drug Resistance in Cancer and Role of Nanomedicine-Based Natural Products. Bioactive Natural Products for the Management of Cancer: from Bench to Bedside 2019. [DOI: 10.1007/978-981-13-7607-8_9] [Reference Citation Analysis]
353 Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treat Res 2019;178:3-43. [PMID: 31209840 DOI: 10.1007/978-3-030-16391-4_1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
354 Koeppen H, Mccleland ML, Kowanetz M. Predictive Biomarkers and Targeted Therapies in Immuno-oncology. Predictive Biomarkers in Oncology 2019. [DOI: 10.1007/978-3-319-95228-4_29] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Lin Z, Gu J, Cui X, Huang L, Li S, Feng J, Liu B, Zhou Y. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression. J Cancer 2019;10:211-22. [PMID: 30662542 DOI: 10.7150/jca.26444] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
356 Andrews SC, Davies M. The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners 2019. [DOI: 10.1007/978-3-030-16550-5_7] [Reference Citation Analysis]
357 Lucas AT, Robinson R, Schorzman AN, Piscitelli JA, Razo JF, Zamboni WC. Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. Antibodies (Basel) 2019;8:E3. [PMID: 31544809 DOI: 10.3390/antib8010003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
358 Arasanz H, Zuazo M, Vera R, Kochan G, Escors D. Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. Lung Cancer Manag 2018;7:LMT07. [PMID: 30713587 DOI: 10.2217/lmt-2018-0014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
359 Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E, Chaft J, Forde PM, Jones DR, Broderick SR. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158:269-276. [PMID: 30718052 DOI: 10.1016/j.jtcvs.2018.11.124] [Cited by in Crossref: 109] [Cited by in F6Publishing: 129] [Article Influence: 21.8] [Reference Citation Analysis]
360 Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res 2019;79:1214-25. [PMID: 30541742 DOI: 10.1158/0008-5472.CAN-18-1127] [Cited by in Crossref: 126] [Cited by in F6Publishing: 145] [Article Influence: 25.2] [Reference Citation Analysis]
361 Hsu PC, Yang CT, Jablons DM, You L. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines 2018;6:E114. [PMID: 30544524 DOI: 10.3390/biomedicines6040114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
362 Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. Transl Lung Cancer Res 2018;7:691-702. [PMID: 30505714 DOI: 10.21037/tlcr.2018.06.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
363 Fenizia F, Pasquale R, Roma C, Bergantino F, Iannaccone A, Normanno N. Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. Transl Lung Cancer Res 2018;7:668-77. [PMID: 30505711 DOI: 10.21037/tlcr.2018.09.23] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
364 Rawluk J, Waller CF. Der Einsatz von Checkpoint-Hemmern beim Lungenkarzinom wird breiter. Pneumo News 2018;10:34-42. [DOI: 10.1007/s15033-018-0819-9] [Reference Citation Analysis]
365 Shen K, Cui J, Wei Y, Chen X, Liu G, Gao X, Li W, Lu H, Zhan P, Lv T, Lin D. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. J Thorac Dis 2018;10:6636-52. [PMID: 30746209 DOI: 10.21037/jtd.2018.11.72] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
366 Grigorescu AC. Immunotherapy in Advanced Lung Cancer Treatment. Lung Cancer - Strategies for Diagnosis and Treatment 2018. [DOI: 10.5772/intechopen.77005] [Reference Citation Analysis]
367 Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol 2018;25:e403-10. [PMID: 30464691 DOI: 10.3747/co.25.4047] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 9.8] [Reference Citation Analysis]
368 Chen S, Hu B, Li H. A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer. Onco Targets Ther 2018;11:7691-7. [PMID: 30464517 DOI: 10.2147/OTT.S171072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
369 Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl) 2018;9:85-90. [PMID: 30498383 DOI: 10.2147/LCTT.S173724] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
370 Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Dô P, Dubos-Arvis C, Chouaïd C, Gervais R. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. Cancer Med 2018;7:5505-13. [PMID: 30311424 DOI: 10.1002/cam4.1825] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
371 Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther 2018;3:26. [PMID: 30275987 DOI: 10.1038/s41392-018-0022-9] [Cited by in Crossref: 120] [Cited by in F6Publishing: 127] [Article Influence: 24.0] [Reference Citation Analysis]
372 Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95. [PMID: 30253811 DOI: 10.1186/s40425-018-0411-1] [Cited by in Crossref: 99] [Cited by in F6Publishing: 104] [Article Influence: 19.8] [Reference Citation Analysis]
373 Kang DH, Chung C, Kim JO, Jung SS, Park HS, Park DI, Jung SY, Park M, Lee JE. Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. Thorac Cancer 2018;9:1500-8. [PMID: 30253080 DOI: 10.1111/1759-7714.12877] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
374 Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 2018;362:k3529. [PMID: 30201790 DOI: 10.1136/bmj.k3529] [Cited by in Crossref: 218] [Cited by in F6Publishing: 229] [Article Influence: 43.6] [Reference Citation Analysis]
375 Fu S, Qu PS, Cai SN. Effect of anesthetic methods on postoperative CD3+, CD4+ and CD4+CD25+ in patients with lung cancer undergoing radical operation. Oncol Lett 2018;16:6547-51. [PMID: 30344761 DOI: 10.3892/ol.2018.9416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
376 Liede A, Hernandez RK, Wade SW, Bo R, Nussbaum NC, Ahern E, Dougall WC, Smyth MJ. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Oncoimmunology 2018;7:e1480301. [PMID: 30524886 DOI: 10.1080/2162402X.2018.1480301] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
377 Lim SW, Ahn MJ. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. Korean J Intern Med 2019;34:50-9. [PMID: 30612418 DOI: 10.3904/kjim.2018.179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
378 Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17:129. [PMID: 30139382 DOI: 10.1186/s12943-018-0864-3] [Cited by in Crossref: 323] [Cited by in F6Publishing: 348] [Article Influence: 64.6] [Reference Citation Analysis]
379 Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight 2018;3:120858. [PMID: 30089719 DOI: 10.1172/jci.insight.120858] [Cited by in Crossref: 80] [Cited by in F6Publishing: 89] [Article Influence: 16.0] [Reference Citation Analysis]
380 Lazzari G, Terlizzi A, Porrazzo G, Devicienti S, Perri F, Della Vittoria Scarpati G, Silvano G. Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. Onco Targets Ther 2018;11:4621-9. [PMID: 30122953 DOI: 10.2147/OTT.S176226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
381 Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 2018;16:219. [PMID: 30081936 DOI: 10.1186/s12967-018-1595-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
382 Jin S, Cao S, Li J, Meng Q, Wang C, Yao L, Lang Y, Cao J, Shen J, Pan B, Hu J, Yu Y. Cancer/testis antigens (CTAs) expression in resected lung cancer. Onco Targets Ther 2018;11:4491-9. [PMID: 30122941 DOI: 10.2147/OTT.S159491] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
383 Testa U, Castelli G, Pelosi E. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers (Basel) 2018;10:E248. [PMID: 30060526 DOI: 10.3390/cancers10080248] [Cited by in Crossref: 150] [Cited by in F6Publishing: 176] [Article Influence: 30.0] [Reference Citation Analysis]
384 Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer 2018;6:69. [PMID: 29996914 DOI: 10.1186/s40425-018-0377-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
385 Lemieux J, Audet S. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada. Curr Oncol 2018;25:S161-70. [PMID: 29910659 DOI: 10.3747/co.25.3846] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
386 Kataoka Y, Hirano K. Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors? Ann Transl Med 2018;6:222. [PMID: 30023385 DOI: 10.21037/atm.2018.04.17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
387 Klein F. Checkpointinhibition beim NSCLC auch längerfristig effektiv. Im Focus Onkologie 2018;21:41-41. [DOI: 10.1007/s15015-018-4044-5] [Reference Citation Analysis]
388 Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int 2018;38:976-87. [PMID: 29603856 DOI: 10.1111/liv.13746] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 26.2] [Reference Citation Analysis]
389 Kim TK, Herbst RS, Chen L. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 2018;39:624-31. [PMID: 29802087 DOI: 10.1016/j.it.2018.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 113] [Article Influence: 20.6] [Reference Citation Analysis]
390 Park S, Kim JY, Lee JC, Kim HR, Song S, Kwon H, Ji W, Choi CM. Mobile Phone App–Based Pulmonary Rehabilitation for Chemotherapy-Treated Patients With Advanced Lung Cancer: Pilot Study (Preprint).. [DOI: 10.2196/preprints.11094] [Reference Citation Analysis]
391 Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 2018;8:822-35. [PMID: 29773717 DOI: 10.1158/2159-8290.CD-18-0099] [Cited by in Crossref: 703] [Cited by in F6Publishing: 773] [Article Influence: 140.6] [Reference Citation Analysis]
392 Wang S, Hao J, Wang H, Fang Y, Tan L. Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer. Oncoimmunology 2018;7:e1457600. [PMID: 30221052 DOI: 10.1080/2162402X.2018.1457600] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
393 Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19:694-704. [PMID: 29628312 DOI: 10.1016/s1470-2045(18)30148-7] [Cited by in Crossref: 227] [Cited by in F6Publishing: 241] [Article Influence: 45.4] [Reference Citation Analysis]
394 Attili I, Karachaliou N, Bonanno L, Berenguer J, Bracht J, Codony-Servat J, Codony-Servat C, Ito M, Rosell R. STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Ther Adv Med Oncol 2018;10:1758835918763744. [PMID: 29636826 DOI: 10.1177/1758835918763744] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
395 Tsiara A, Liontos M, Kaparelou M, Zakopoulou R, Bamias A, Dimopoulos MA. Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Ann Transl Med 2018;6:144. [PMID: 29862233 DOI: 10.21037/atm.2018.02.07] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
396 Salati M, Baldessari C, Cerbelli B, Botticelli A. Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution. Transl Lung Cancer Res 2018;7:S91-4. [PMID: 29782565 DOI: 10.21037/tlcr.2018.01.14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
397 Karachaliou N, Rosell R. Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. Ther Adv Med Oncol 2018;10:1758835918763723. [PMID: 29619092 DOI: 10.1177/1758835918763723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
398 Inamura K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers (Basel) 2018;10:E72. [PMID: 29538329 DOI: 10.3390/cancers10030072] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 11.6] [Reference Citation Analysis]
399 Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, Adusumilli PS. Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. Ann Thorac Surg 2018;106:178-83. [PMID: 29550207 DOI: 10.1016/j.athoracsur.2018.02.030] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
400 Guo Z, Meng C, Wei X, Tang C, Liang J. Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. Thorac Cancer 2018;9:646-51. [PMID: 29498219 DOI: 10.1111/1759-7714.12600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
401 McCoach CE, Bivona TG. The evolving understanding of immunoediting and the clinical impact of immune escape. J Thorac Dis 2018;10:1248-52. [PMID: 29708132 DOI: 10.21037/jtd.2018.03.60] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
402 Nakano K, Kitahara Y, Mito M, Seno M, Sunada S. Development of the Japanese version of an information aid to provide accurate information on prognosis to patients with advanced non-small-cell lung cancer receiving chemotherapy: a pilot study. BMC Palliat Care 2018;17:38. [PMID: 29482526 DOI: 10.1186/s12904-018-0292-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
403 Morabito A. Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients? BMC Med 2018;16:24. [PMID: 29448944 DOI: 10.1186/s12916-018-1011-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
404 Das S, Gibson MK. Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma. Oncol Hematol Rev 2018;14:82-8. [PMID: 31119034 DOI: 10.17925/OHR.2018.14.2.82] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
405 Borrie AE, Maleki Vareki S. T Lymphocyte–Based Cancer Immunotherapeutics. International Review of Cell and Molecular Biology 2018. [DOI: 10.1016/bs.ircmb.2018.05.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
406 Cho JH. Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. Immune Netw 2017;17:378-91. [PMID: 29302251 DOI: 10.4110/in.2017.17.6.378] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 7.8] [Reference Citation Analysis]
407 Ma L, Qin N, Zhang X, Wu Y, Li H, Yu M, Liu Z, Wang J. [Analysis of the Efficacy of Immunotherapy on the Posterior Lines 
of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:338-44. [PMID: 34034457 DOI: 10.3779/j.issn.1009-3419.2021.104.06] [Reference Citation Analysis]
408 Guo X, Wen T, Qu X. [Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors 
Based Combination Therapy]. Zhongguo Fei Ai Za Zhi 2021;24:513-8. [PMID: 34275517 DOI: 10.3779/j.issn.1009-3419.2021.101.26] [Reference Citation Analysis]